<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for managing medication‐related osteonecrosis of the jaw - Beth-Tasdogan, NH - 2022 | Cochrane Library</title> <meta content="Interventions for managing medication‐related osteonecrosis of the jaw - Beth-Tasdogan, NH - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012432.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for managing medication‐related osteonecrosis of the jaw - Beth-Tasdogan, NH - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012432.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012432.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for managing medication‐related osteonecrosis of the jaw" name="citation_title"/> <meta content="Natalie H Beth-Tasdogan" name="citation_author"/> <meta content="Ulm University" name="citation_author_institution"/> <meta content="Benjamin Mayer" name="citation_author"/> <meta content="Ulm University" name="citation_author_institution"/> <meta content="Heba Hussein" name="citation_author"/> <meta content="Faculty of Dentistry, Cairo University" name="citation_author_institution"/> <meta content="Oliver Zolk" name="citation_author"/> <meta content="Brandenburg Medical School Theodor Fontane" name="citation_author_institution"/> <meta content="oliver.zolk@mhb-fontane.de" name="citation_author_email"/> <meta content="Jens-Uwe Peter" name="citation_author"/> <meta content="Brandenburg Medical School Theodor Fontane" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012432.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/07/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012432.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012432.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012432.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Bacterial Agents [therapeutic use]; Denosumab [adverse effects]; Diphosphonates [adverse effects]; *Osteonecrosis; *Osteoporosis [drug therapy]; Teriparatide" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012432.pub3&amp;doi=10.1002/14651858.CD012432.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="PSzzz2OT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012432\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012432\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012432.pub3",title:"Interventions for managing medication\\u2010related osteonecrosis of the jaw",firstPublishedDate:"Jul 12, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Oral Health Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012432.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012432.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012432.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012432.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012432.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012432.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012432.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012432.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012432.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012432.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7764 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012432.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-sec-0124"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-sec-0024"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-sec-0025"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-sec-0118"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/appendices#CD012432-sec-0133"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/supinfo/CD012432StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/supinfo/CD012432StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for managing medication‐related osteonecrosis of the jaw</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information#CD012432-cr-0004">Natalie H Beth-Tasdogan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information#CD012432-cr-0005">Benjamin Mayer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information#CD012432-cr-0006">Heba Hussein</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information#CD012432-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Oliver Zolk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information#CD012432-cr-0008">Jens-Uwe Peter</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information/en#CD012432-sec-0143">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 July 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012432.pub3">https://doi.org/10.1002/14651858.CD012432.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012432-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012432-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012432-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012432-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012432-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012432-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012432-abs-0001" lang="en"> <section id="CD012432-sec-0001"> <h3 class="title" id="CD012432-sec-0001">Background</h3> <p>Medication‐related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab, and antiangiogenic agents), and involves the progressive destruction of bone in the mandible or maxilla. Depending on the drug, its dosage, and the duration of exposure, this adverse drug reaction may occur rarely (e.g. following the oral administration of bisphosphonate or denosumab treatments for osteoporosis, or antiangiogenic agent‐targeted cancer treatment), or commonly (e.g. following intravenous bisphosphonate for cancer treatment). MRONJ is associated with significant morbidity, adversely affects quality of life (QoL), and is challenging to treat. This is an update of our review first published in 2017. </p> </section> <section id="CD012432-sec-0002"> <h3 class="title" id="CD012432-sec-0002">Objectives</h3> <p>To assess the effects of interventions versus no treatment, placebo, or an active control for the prophylaxis of MRONJ in people exposed to antiresorptive or antiangiogenic drugs. </p> <p>To assess the effects of non‐surgical or surgical interventions (either singly or in combination) versus no treatment, placebo, or an active control for the treatment of people with manifest MRONJ. </p> </section> <section id="CD012432-sec-0003"> <h3 class="title" id="CD012432-sec-0003">Search methods</h3> <p>Cochrane Oral Health’s Information Specialist searched four bibliographic databases up to 16 June 2021 and used additional search methods to identify published, unpublished, and ongoing studies.  </p> </section> <section id="CD012432-sec-0004"> <h3 class="title" id="CD012432-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing one modality of intervention with another for the prevention or treatment of MRONJ. For 'prophylaxis of MRONJ', the primary outcome of interest was the incidence of MRONJ; secondary outcomes were QoL, time‐to‐event, and rate of complications and side effects of the intervention. For 'treatment of established MRONJ', the primary outcome of interest was healing of MRONJ; secondary outcomes were QoL, recurrence, and rate of complications and side effects of the intervention. </p> </section> <section id="CD012432-sec-0005"> <h3 class="title" id="CD012432-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the search results, extracted the data, and assessed the risk of bias in the included studies. For dichotomous outcomes, we reported the risk ratio (RR) (or rate ratio) and 95% confidence intervals (CIs). </p> </section> <section id="CD012432-sec-0006"> <h3 class="title" id="CD012432-sec-0006">Main results</h3> <p>We included 13 RCTs (1668 participants) in this updated review, of which eight were new additions. The studies were clinically diverse and examined very different interventions, so meta‐analyses could not be performed. </p> <p>We have low or very low certainty about available evidence on interventions for the prophylaxis or treatment of MRONJ. </p> <p><b>Prophylaxis of MRONJ</b> </p> <p>Five RCTs examined different interventions to prevent the occurrence of MRONJ.</p> <p>One RCT compared standard care with regular dental examinations at three‐month intervals and preventive treatments (including antibiotics before dental extractions and the use of techniques for wound closure that avoid exposure and contamination of bone) in men with metastatic prostate cancer treated with zoledronic acid. The intervention seemed to lower the risk of MRONJ (RR 0.10, 95% CI 0.02 to 0.39, 253 participants). Secondary outcomes were not evaluated. </p> <p>Dentoalveolar surgery is considered a common predisposing event for developing MRONJ and five RCTs tested various preventive measures to reduce the risk of postoperative MRONJ. The studies evaluated plasma rich in growth factors inserted into the postextraction alveolus in addition to standardised medical and surgical care versus standardised medical and surgical care alone (RR 0.08, 95% CI 0.00 to 1.51, 176 participants); delicate surgery and closure by primary intention versus non‐traumatic tooth avulsion and closure by secondary intention (no case of postoperative MRONJ in either group); primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet‐rich fibrin without primary wound closure (no case of postoperative MRONJ in either group); and subperiosteal wound closure versus epiperiosteal wound closure (RR 0.09, 95% CI 0.00 to 1.56, 132 participants).  </p> <p><b>Treatment of MRONJ</b> </p> <p>Eight RCTs examined different interventions for the treatment of established MRONJ; that is, the effect on MRONJ cure rates.  </p> <p>One RCT analysed hyperbaric oxygen (HBO) treatment used in addition to standard care (antiseptic rinses, antibiotics, and surgery) compared with standard care alone (at last follow‐up: RR 1.56, 95% CI 0.77 to 3.18, 46 participants).  </p> <p>Healing rates from MRONJ were not significantly different between autofluorescence‐guided bone surgery and conventional bone surgery (RR 1.08, 95% CI 0.85 to 1.37, 30 participants). Another RCT that compared autofluorescence‐ with tetracycline fluorescence‐guided sequestrectomy for the surgical treatment of MRONJ found no significant difference (at one‐year follow‐up: RR 1.05, 95% CI 0.86 to 1.30, 34 participants).  </p> <p>Three RCTs investigated the effect of growth factors and autologous platelet concentrates on healing rates of MRONJ: platelet‐rich fibrin after bone surgery versus surgery alone (RR 1.05, 95% CI 0.90 to 1.22, 47 participants), bone morphogenetic protein‐2 together with platelet‐rich fibrin versus platelet‐rich fibrin alone (RR 1.10, 95% CI 0.94 to 1.29, 55 participants), and concentrated growth factor and primary wound closure versus primary wound closure only (RR 1.38, 95% CI 0.81 to 2.34, 28 participants).   </p> <p>Two RCTs focused on pharmacological treatment with teriparatide: teriparatide 20 μg daily versus placebo in addition to standard care (RR 0.96, 95% CI 0.31 to 2.95, 33 participants) and teriparatide 56.5 μg weekly versus teriparatide 20 μg daily in addition to standard care (RR 1.60, 95% CI 0.25 to 1.44, 12 participants).  </p> </section> <section id="CD012432-sec-0007"> <h3 class="title" id="CD012432-sec-0007">Authors' conclusions</h3> <p><b>Prophylaxis of medication‐related osteonecrosis of the jaw</b> </p> <p>One open‐label RCT provided some evidence that dental examinations at three‐month intervals and preventive treatments may be more effective than standard care for reducing the incidence of medication‐related osteonecrosis of the jaw (MRONJ) in individuals taking intravenous bisphosphonates for advanced cancer. We assessed the certainty of the evidence to be very low. </p> <p>There is insufficient evidence to either claim or refute a benefit of the interventions tested for prophylaxis of MRONJ in patients with antiresorptive therapy undergoing dentoalveolar surgery. Although some interventions suggested a potential large effect, the studies were underpowered to show statistical significance, and replication of the results in larger studies is pending. </p> <p><b>Treatment of medication‐related osteonecrosis of the jaw</b> </p> <p>The available evidence is insufficient to either claim or refute a benefit, in addition to standard care, of any of the interventions studied for the treatment of MRONJ.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012432-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012432-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012432-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012432-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012432-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012432-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012432-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012432-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012432-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012432-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012432-abs-0002" lang="en"> <h3>Interventions for managing medication‐related osteonecrosis (severe bone damage) of the jaw </h3> <p><b>Review question</b> </p> <p>What are the effects of different interventions to either prevent or treat medication‐related osteonecrosis of the jaw compared with each other or compared with no treatment or an inactive intervention ('placebo')? </p> <p><b>Background</b> </p> <p>Medication‐related osteonecrosis of the jaw (MRONJ) is severe bone damage in the jaw bone that occurs in some people as a reaction to certain medicines commonly used in the treatment of cancer and osteoporosis (a disease that makes bones fragile). It is a painful condition that can be difficult to treat. MRONJ occurs rarely in people taking some medicines for osteoporosis. However, in people receiving these drugs at higher doses for cancer‐related conditions, the risk of MRONJ may be higher and has been reported to occur in up to five in 100 individuals. It is important to identify effective preventive measures to reduce the risk of MRONJ, and better treatments for those who have it. </p> <p>This is an update of our review first published in 2017. It is based on a search for articles that was conducted most recently in June 2021. </p> <p><b>Study</b> <b>characteristics</b> </p> <p>Working with <a href="http://oralhealth.cochrane.org/" target="_blank">Cochrane Oral Health</a>, we searched for studies that had been published up to June 2021. We found five studies that focused on the prevention of MRONJ and eight studies that tested treatments for MRONJ. The studies involved 1668 adults, with the smallest study having 13 participants and the largest study having 700 participants. Most study participants were women, but one study was of men with prostate cancer receiving bisphosphonate infusions (given by drip into a vein). All but two studies included only participants treated with bisphosphonates (used to support treatment and reduce risk of fracture and bone pain), although several other drugs are also known to induce MRONJ. Two trials also included patients treated with bisphosphonates or denosumab. </p> <p><b>Key</b> <b>results</b> </p> <p>One study provided very low‐certainty evidence that dental examinations at three‐month intervals and preventive treatments (antibiotics before dental extractions and the use of techniques for wound closure that avoid exposure and contamination of bone) are more effective than standard care for reducing the number of cases with MRONJ in a group of people receiving intravenous bisphosphonates for cancer‐related conditions. In the experimental group, which received preventive care consisting of antibiotics and specific wound closure, fewer people developed MRONJ: two participants per 100 who underwent close monitoring developed MRONJ compared to 23 participants per 100 in the control group (standard care). </p> <p>There was insufficient evidence to conclude that the use of the other interventions investigated would reduce the risk of MRONJ or would improve healing of MRONJ. </p> <p><b>Certainty of evidence</b> </p> <p>The certainty of evidence was low or very low. This was due to limitations in how the studies were designed and run. For example, some participants changed groups during the study, some participants did not finish the study, and the outcomes were measured at different follow‐up times. In addition, most of the studies had only a small number of participants. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012432-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012432-sec-0124"></div> <h3 class="title" id="CD012432-sec-0125">Implications for practice</h3> <section id="CD012432-sec-0125"> <section id="CD012432-sec-0126"> <h5 class="title">Prophylaxis of MRONJ</h5> <p>We identified five randomised controlled trials (RCTs) that evaluated various interventions for the prophylaxis of medication‐related osteonecrosis of the jaw (MRONJ).  </p> <p>One open‐label RCT provided very low‐certainty evidence that dental examinations at three‐month intervals plus preventive treatments are more effective than standard care in reducing the incidence of MRONJ in men taking intravenous bisphosphonates for advanced cancer and bone metastases (<a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>). Our conclusion from the study is that people receiving intravenous bisphosphonates for advanced cancer and bone metastases should be placed on a regular recall schedule. Recall visits should include a check of oral hygiene, periodontal diseases, cavities, and effective infection control. Of note, 29% of participants randomly allocated to the experimental arm later declined to have frequent dental check‐up visits (<a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>). Given that the adherence rates observed in clinical trials generally exceed those observed in a real‐life setting, the limited acceptance of a dental monitoring programme among such individuals may limit the success of this preventive intervention. Thus, the motivation of these individuals is very important. The applicability of the study results to populations other than individuals with cancer taking intravenous bisphosphonates is unclear. </p> <p>With dentoalveolar surgery being considered a major risk factor for developing MRONJ, five RCTs evaluated interventions that were proposed to reduce the incidence of MRONJ in individuals undergoing dental extractions. There was insufficient evidence to either claim or refute a benefit of any of the tested interventions for the prophylaxis of MRONJ. The small sample size relative to the low event rate of MRONJ may have contributed to the lack of a measurable effect. As we are unable to draw definitive conclusions about these interventions and techniques, we cannot make any clinical recommendations regarding them. </p> </section> <section id="CD012432-sec-0127"> <h5 class="title">Treatment of MRONJ</h5> <p>We found eight RCTs that compared regimens for treating MRONJ. There was insufficient evidence to either claim or refute a benefit of any of the tested interventions for the treatment of MRONJ. The small sample size may have contributed to a lack of measurable effect. Moreover, methodological constraints of the trials were associated with a high risk of bias, contributing to uncertainty about any estimates of effect. </p> </section> </section> <h3 class="title" id="CD012432-sec-0128">Implications for research</h3> <section id="CD012432-sec-0128"> <section id="CD012432-sec-0129"> <h5 class="title">Prophylaxis of MRONJ</h5> <p>Incidence rates for MRONJ depend on the specific drug, its dose, and the duration of treatment, and range from 0.004% to 6.7% (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). Thus, depending on the population under investigation and the specific at‐risk drug therapy, studies may require several hundred to several thousand participants to provide sufficient statistical power to detect meaningful effects of preventive measures on the incidence of MRONJ. Although dentoalveolar surgery is considered a common predisposing event for developing MRONJ (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>), well‐designed RCTs are lacking to identify effective preventive strategies in individuals at risk undergoing dentoalveolar surgery. Importantly, the concept of 'a drug holiday' (stopping the antiresorptive medication) in individuals receiving oral bisphosphonates or denosumab who require tooth extractions is a matter of debate and requires future research (<a href="./references#CD012432-bbs2-0060" title="DammDD , JonesDM . Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. General Dentistry2013;61(5):33-8. [PMID: 23928436]">Damm 2013</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). </p> </section> <section id="CD012432-sec-0130"> <h5 class="title">Treatment of MRONJ</h5> <p>Future RCTs should address important practice‐related research questions, namely the comparison of surgical versus non‐surgical protocols or conservative versus aggressive surgical protocols for the stage‐specific treatment of MRONJ. Moreover, the evaluation of add‐on effects for adjunct treatments such as HBO, α‐tocopherol, pentoxifylline, ozone therapy, or low‐level laser therapy, is important. Blinding of participants and clinicians (surgeons) may not be possible because of the nature of most interventions, but efforts should be made to ensure the blinding of outcome assessors (data collectors), which is crucial to ensure unbiased outcome assessment. One important limitation of existing RCTs was the small sample size. The sample size of future trials should be appropriate to allow meaningful conclusions to be drawn. In order to deal with the rare event rates of MRONJ, future trials should preferably follow a multicentric design and include sufficient participating centres. This will facilitate reaching a large number of cases. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012432-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012432-sec-0008"></div> <div class="table" id="CD012432-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dental examinations at three‐month intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dental examinations at three‐month intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people at risk of MRONJ<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> dental examinations at three‐month intervals and preventive treatments (experimental)<br/><b>Comparison:</b> standard care (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard care (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dental examinations at 3‐month intervals and preventive treatments (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRONJ (incidence proportion)</b><br/>Diagnostic criteria for MRONJ: non‐healing exposed bone in mandible or maxilla for longer than 8 weeks without any change of the stage of disease </p> <p> </p> <p>Follow‐up: mean 32 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(5 to 91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.10</b><br/>(0.02 to 0.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants: high‐risk (i.e. individuals with cancer exposed to intravenous zoledronic acid). </p> <p>The outcome MRONJ was also reported as number of cases per patient‐year (incidence rate): rate ratio 0.18 (95% CI 0.04 to 0.74). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to very serious risk of bias (high and unbalanced rate of crossovers after randomisation; high dropout rates due to high mortality; failure to adhere to the intention‐to‐treat principle; mean follow‐up differed between experimental and control groups) and very serious limitation of indirectness (all male and high‐risk patients). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012432-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to a standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people treated with IV bisphosphonates who need dental extractions<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> dental extraction protocol with PRGF (experimental)<br/><b>Comparison:</b> standard dental extraction protocol without PRGF (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard dental extraction protocol without PRGF (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dental extraction protocol with PRGF (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRONJ (incidence proportion)</b><br/>Diagnostic criteria of MRONJ: pain, swelling, and non‐healing exposed necrotic bone or fistulae, or both, with connection to the bone<br/>  </p> <p>Follow‐up: 24‐60 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b><br/>(0 to 89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.08</b><br/>(0.00 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants: high risk, i.e. individuals with cancer exposed to IV zoledronic acid</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>IV:</b> intravenous: <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of evidence by three levels due to imprecision and very serious risk of bias (high or unclear risk of selection bias, performance bias, detection bias, and attrition bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012432-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people on antiresorptive treatment<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> subperiosteal wound closure<br/><b>Comparison:</b> epiperiosteal wound closure after tooth extraction </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with epiperiosteal wound closure after tooth extraction</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with subperiosteal wound closure after tooth extraction</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRONJ after tooth extraction</b> Assessed with: absence of complete mucosal integrity </p> <p> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b><br/>(0 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.09</b><br/>(0.00 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 patients changed intervention from epiperiosteal wound closure to subperiosteal wound closure. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by two levels due to imprecision and serious risk of bias (unclear selection bias, detection bias, high risk of performance bias, attrition bias and reporting bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012432-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hyperbaric oxygen therapy (HBO) as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HBO as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people with MRONJ<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> HBO as an adjunct to conventional therapy (experimental)<br/><b>Comparison:</b> conventional therapy (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with conventional therapy (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with HBO therapy as an adjunct to conventional therapy (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ</b><br/>Diagnostic criteria for healing of MRONJ: gingival coverage with no exposed bone </p> <p> </p> <p>Follow‐up: up to 24 months (outcome was measured at last follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>520 per 1000</b><br/>(257 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.56</b><br/>(0.77 to 3.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HBO:</b> hyperbaric oxygen therapy; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to imprecision and very serious risk of bias (unclear and high risk of selection bias, performance bias, detection bias, and attrition bias; failure to adhere to the intention‐to‐treat principle). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012432-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Autofluorescence‐guided bone surgery (experimental) compared to tetracycline fluorescence‐guided bone surgery (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Autofluorescence‐guided bone surgery (experimental) compared to tetracycline fluorescence‐guided bone surgery (control) for treatment of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people with MRONJ<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> autofluorescence‐guided bone surgery (experimental)<br/><b>Comparison:</b> tetracycline fluorescence‐guided bone surgery (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with tetracycline fluorescence‐guided bone surgery (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with autofluorescence‐guided bone surgery (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ</b><br/>Criteria for healing of MRONJ: mucosal integrity </p> <p> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>889 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>933 per 1000</b><br/>(764 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/>(0.86 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 <br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to imprecision and very serious risk of bias (unclear and high risk of selection bias, performance bias, and detection bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012432-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) compared to platelet‐rich fibrin alone (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) compared to platelet‐rich fibrin alone (control) for treatment of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) </p> <p><b>Comparison:</b> platelet‐rich fibrin only (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with platelet‐rich fibrin only (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with bone morphogenetic protein‐2 adjacent to platelet‐rich fibrin (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ </b> </p> <p>Defined in the study as full coverage with absence of exposed bone, mucosal swelling and erythema, purulent drainage, intra‐ and extra oral fistula and/or any pain or discomfort </p> <p> </p> <p>Follow‐up: 16 weeks post surgery</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>880 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>968 per 1000</b><br/>(831 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b> (0.94 to 1.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 <br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to very serious limitations of imprecision and very serious risk of bias (unclear risk of selection bias, detection bias, high risk of performance bias, attrition bias, reporting bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012432-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Autofluorescence‐guided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Autofluorescence‐guided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> autofluorescence guided surgery (experimental) </p> <p><b>Comparison:</b> conventional surgery (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with conventional surgery (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with autofluorescence guided surgery (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ </b> </p> <p>Criteria for healing: absence of bone exposure</p> <p> </p> <p>Follow‐up: 1 year (at last follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>867 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>933 per 1000</b><br/>(734 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> (0.85 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High drop‐out rate. 6 patients were excluded due to mortality and no show at follow‐up appointments. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty  of the evidence by three levels due to very serious imprecision and serious risk of bias (high selection bias, performance bias, attrition bias, unclear risk of detection bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012432-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> platelet‐rich fibrin (experimental) </p> <p><b>Comparison:</b> conventional (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgery alone (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with platelet‐rich fibrin after bone surgery (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ</b> Defined as absence of infection and mucosal integrity without fistula </p> <p> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>913 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>958 per 1000</b><br/>(824 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> (0.90 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome healing of MRONJ was also reported as absence of infection, mucosal integrity without fistula, no need for re‐intervention: rate ratio 1.60 (95% CI 1.04 to 2.46). Follow‐up: 1 year </p> <p>See <a href="./references#CD012432-fig-0012" title="">Analysis 8.2</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to very serious limitation of imprecision and serious risk of bias (unclear selection bias, detection bias, high risk of performance bias, reporting bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012432-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Concentrated growth factor and primary wound closure (experimental) versus primary wound closure only (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Concentrated growth factor and primary wound closure compared with primary wound closure only for treatment of MRONJ </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people with MRONJ<br/><b>Setting: </b> surgical treatment<br/><b>Intervention:</b> concentrated growth factor and primary wound closure<br/><b>Comparison:</b> primary wound closure only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with primary wound closure only (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with concentrated growth factor and primary wound closure (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ</b> Defined as soft tissue healing<br/>Assessed with: mucosal integrity (without flap dehiscence or infection) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>521 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b><br/>(89 to 922) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.38</b><br/>(0.81 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels because of serious risk of bias (unclear selection bias, high risk of performance bias), very serious limitation of indirectness (only female participants with osteoporosis) and very serious limitation of imprecision (few participants). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012432-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Teriparatide 20 μg daily (experimental) versus placebo (control) in addition to standard care for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Teriparatide 20 μg daily compared with placebo for treatment of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> people  with MRONJ </p> <p><b>Settings:</b> outpatient and inpatient treatment </p> <p><b>Intervention:</b> teriparatide 20 μg daily </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with teriparatide 20 µg daily (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Healing of MRONJ</b> </p> <p>Primary outcomes were the clinical and radiologic resolution of MRONJ lesions, as evaluated by oral examination and CBCT imaging; secondary outcomes included improvement in MRONJ stage, change in MRONJ lesion size, quality of life, bone mineral density, and evidence of osteoblastic response measured biochemically using P1NP and radiologically using 18F‐fluoride PET‐CT imaging </p> <p> </p> <p>Last follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> <p>(87 to 819)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96  </b>(0.31 to 2.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 33</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by two levels due to imprecision and serious risk of bias (unclear selection bias, high risk of attrition bias and reporting bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012432-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Teriparatide 56.5 μg weekly (experimental) versus teriparatide 20 μg daily (control) in addition to standard care for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Teriparatide 56.5 μg weekly (experimental) compared with teriparatide 20 μg daily (control) in addition to standard care for treatment of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> outpatient and inpatient treatment </p> <p><b>Intervention:</b> teriparatide 56.5 μg weekly in addition to standard care </p> <p><b>Comparison:</b> teriparatide 20 μg daily in addition to standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with teriparatide 20 μg daily (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with teriparatide 56.5 µg weekly (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ</b> </p> <p>Measured changes in MRONJ clinical stage at 6 months after the start of the treatment as clinical course, changes in bone metabolism (using bone scintigraphy), percentage of bone formation on the osteolysis of MRONJ, and measurement of bone turnover markers) </p> <p> </p> <p>Follow‐up: 6 months after start of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> <b>300 per 1000</b> (125 to 721) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> </p> <p>(0.25 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 12</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to imprecision and very serious risk of bias (unclear selection bias and detection bias, high risk of performance bias, attrition bias and reporting bias). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012432-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012432-sec-0009"></div> <section id="CD012432-sec-0010"> <h3 class="title" id="CD012432-sec-0010">Description of the condition</h3> <p>Medication‐related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab and antiangiogenic agents), and involves the progressive destruction of bone in the mandible or maxilla. </p> <p>Osteonecrosis of the jaw (ONJ) associated with bisphosphonate treatment was first reported in 2003 (<a href="./references#CD012432-bbs2-0091" title="MarxRE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery2003;61(9):1115–7. [PMID: 12966493]">Marx 2003</a>; <a href="./references#CD012432-bbs2-0093" title="MiglioratiCA . Bisphosphanates and oral cavity avascular bone necrosis. Journal of Clinical Oncology2003;21(22):4253-4. [DOI: 10.1200/JCO.2003.99.132] [PMID: 14615459]">Migliorati 2003</a>; <a href="./references#CD012432-bbs2-0106" title="RuggieroSL . Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clinical Cases in Mineral and Bone Metabolism2007;4(1):37-42. [DOI: 10.1016/j.joms.2014.04.031] [PMID: 25234529]">Ruggiero 2007</a>; <a href="./references#CD012432-bbs2-0110" title="Sigua-RodriguezEA , da Costa RibeiroR , deBritoAC , Alvarez-PinzonN , deAlbergaria-BarbosaJR . Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. International Journal of Dentistry2014;2014:192320. [PMID: 24868206]">Sigua‐Rodriguez 2014</a>). Subsequently, ONJ was observed in individuals who took denosumab, an antiresorptive medication unrelated to the bisphosphonate class (<a href="./references#CD012432-bbs2-0051" title="BoneHG , WagmanRB , BrandiML , BrownJP , ChapurlatR , CummingsSR , et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. lancet. Diabetes &amp; Endocrinology2017;5(7):513-23. [DOI: 10.1016/S2213-8587(17)30138-9] [PMID: 28546097]">Bone 2017</a>). A growing number of case reports currently suggest that ONJ is also associated with antiangiogenic agents such as bevacizumab, aflibercept, sunitinib, temsirolimus, and everolimus (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>; <a href="./references#CD012432-bbs2-0116" title="ZhangX , HamadehIS , SongS , KatzJ , MorebJS , LangaeeTY , et al. Osteonecrosis of the jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). Journal of Bone and Mineral Research2010;31(2):336-40. [DOI: 10.1002/jbmr.2693] [PMID: 26288087]">Zhang 2016</a>). The condition formerly referred to as 'bisphosphonate‐related ONJ' has been renamed 'medication‐related ONJ' due to the growing number of ONJ cases associated with non‐bisphosphonate treatments (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). </p> <p>The exact mechanisms underlying MRONJ remain unknown. Interestingly, MRONJ is primarily limited to the maxillofacial region. In contrast to other skeletal bones, jaw bones (the alveolar process and periodontium) have relatively high vascularity, bone turnover, and remodelling because of continuous mechanical stress, which may make them vulnerable to the adverse effects of drugs. Proposed hypotheses that attempt to explain the localisation of MRONJ exclusively to the jaws include altered bone remodelling, angiogenesis inhibition, constant microtrauma, suppression of innate or acquired immunity, and possible effects of inflammation or infection (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). </p> <p>According to the case definition provided by the American Society for Bone and Mineral Research and the American Association of Oral and Maxillofacial Surgeons, people may be considered to have MRONJ if all of the following characteristics are present: (i) current or previous treatment with antiresorptive or antiangiogenic agents, (ii) exposed or necrotic bone in the maxillofacial region that did not heal (by primary or secondary intent) within eight weeks after identification by a healthcare provider, (iii) no history of radiation therapy to the jaws, and (iv) no evidence of metastatic disease to the jaws (<a href="./references#CD012432-bbs2-0106" title="RuggieroSL . Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clinical Cases in Mineral and Bone Metabolism2007;4(1):37-42. [DOI: 10.1016/j.joms.2014.04.031] [PMID: 25234529]">Ruggiero 2007</a>; <a href="./references#CD012432-bbs2-0110" title="Sigua-RodriguezEA , da Costa RibeiroR , deBritoAC , Alvarez-PinzonN , deAlbergaria-BarbosaJR . Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. International Journal of Dentistry2014;2014:192320. [PMID: 24868206]">Sigua‐Rodriguez 2014</a>). MRONJ has been divided into four stages based on clinical symptoms. Stage 0 describes individuals with prodromal disease (unexposed variant). Bone exposure is common in individuals with stage 1 to 3 MRONJ without infection (stage 1), with infection (stage 2), or with infection as well as a pathological fracture or fistula, or evidence of osteolysis extending to the inferior border of the mandible or sinus floor (stage 3) (<a href="#CD012432-tbl-0012">Table 1</a>) (<a href="./references#CD012432-bbs2-0106" title="RuggieroSL . Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clinical Cases in Mineral and Bone Metabolism2007;4(1):37-42. [DOI: 10.1016/j.joms.2014.04.031] [PMID: 25234529]">Ruggiero 2007</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>; <a href="./references#CD012432-bbs2-0110" title="Sigua-RodriguezEA , da Costa RibeiroR , deBritoAC , Alvarez-PinzonN , deAlbergaria-BarbosaJR . Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. International Journal of Dentistry2014;2014:192320. [PMID: 24868206]">Sigua‐Rodriguez 2014</a>; <a href="./references#CD012432-bbs2-0113" title="VescoviP . Bisphosphonates and osteonecrosis: an open matter. Clinical Cases in Mineral and Bone Metabolism2012;9(3):142-4. [PMID: 23289026]">Vescovi 2012a</a>). </p> <div class="table" id="CD012432-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Clinical staging of MRONJ</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRONJ stage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT RISK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No apparent necrotic bone in patients who have been treated with oral or intravenous bisphosphonates </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>STAGE 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No clinical evidence of necrotic bone but nonspecific clinical findings, radiographic changes, and symptoms </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>STAGE 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exposed and necrotic bone or fistulas that probes to bone in patients who are asymptomatic and have no evidence of infection </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>STAGE 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exposed and necrotic bone or fistulas that probes to bone associated with infection as evidenced by pain and erythema in the region of exposed bone with or without purulent drainage </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>STAGE 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exposed and necrotic bone or a fistula that probes to bone in patients with pain, infection, and ≥ 1 of the following: exposed and necrotic bone extending beyond the region of alveolar bone (i.e. inferior border and ramus in mandible, maxillary sinus, and zygoma in maxilla) resulting in pathologic fracture, extraoral fistula, oral antral, or oral nasal communication, or osteolysis extending to inferior border of the mandible or sinus floor </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>From the American Association of Oral and Maxillofacial Surgeons position paper on medication‐related osteonecrosis of the jaw‐‐2014 update (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>) </p> </div> </div> <p>The frequency of MRONJ is highly variable and ranges from very rare (less than 1/10,000) to common (1/100 or more), depending on the drug, treatment indication (cancer versus osteoporosis), dose, and duration of treatment (<a href="./references#CD012432-bbs2-0064" title="DodsonTB . The frequency of medication-related ssteonecrosis of the jaw and its associated risk factors. Oral and Maxillofacial Surgery Clinics of North America2015;27(4):509-16. [DOI: 10.1016/j.coms.2015.06.003] [PMID: 26362367]">Dodson 2015</a>). For example, in randomised controlled trials (RCTs) and a meta‐analysis, the incidence of MRONJ in individuals with cancer exposed to intravenous (IV) zoledronic acid was between 0.3% and 5% (<a href="./references#CD012432-bbs2-0057" title="ColemanR , WoodwardE , BrownJ , CameronD , BellR , DodwellD , et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment2011;127(2):429-38. [DOI: 10.1007/s10549-011-1429-y] [PMID: 21394500]">Coleman 2011</a>; <a href="./references#CD012432-bbs2-0089" title="Lopez-OlivoMA , ShahNA , PrattG , RisserJM , SymanskiE , Suarez-AlmazorME . Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Supportive Care in Cancer2012;20(11):2985-98. [DOI: 10.1007/s00520-012-1563-z] [PMID: 22956190]">Lopez‐Olivo 2012</a>; <a href="./references#CD012432-bbs2-0092" title="MauriD , ValachisA , PolyzosIP , PolyzosNP , KamposiorasK , PesceLL . Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Research and Treatment2009;116(3):433-9. [DOI: 10.1007/s10549-009-0432-z] [PMID: 19521766]">Mauri 2009</a>; <a href="./references#CD012432-bbs2-0096" title="MorganGJ , DaviesFE , GregoryWM , CocksK , BellSE , SzubertAJ , et al, National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet2010;376(9757):1989-99. [DOI: 10.1016/S0140-6736(10)62051-X] [PMID: 21131037]">Morgan 2010</a>). The reported risk of MRONJ in individuals with cancer treated with denosumab ranged from 0.7% to 1.9% (<a href="./references#CD012432-bbs2-0052" title="Boquete-CastroA , Gómez-MorenoG , Calvo-GuiradoJL , Aguilar-SalvatierraA , Delgado-RuizRA . Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clinical Oral Implants Research2016;27(3):367-75. [DOI: 10.1111/clr.12556] [PMID: 25639776]">Boquete‐Castro 2016</a>; <a href="./references#CD012432-bbs2-0101" title="QiWX , TangLN , HeAN , YaoY , ShenZ . Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. International Journal of Clinical Oncology2014;19(2):403-10. [DOI: 10.1007/s10147-013-0561-6] [PMID: 23605142]">Qui 2014</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). A meta‐analysis that compared the safety of denosumab and zoledronic acid in individuals with bone metastases did not reveal a significant difference in the risk of MRONJ between the denosumab and zoledronic acid groups (<a href="./references#CD012432-bbs2-0055" title="ChenF , PuF . Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. Oncology Research and Treatment2016;39(7-8):453-9. [DOI: 10.1159/000447372] [PMID: 27487236]">Chen 2016</a>). </p> <p>Among individuals with osteoporosis, who receive substantially lower doses of bisphosphonates or denosumab than those with cancer, MRONJ is rare and the incidence may not be substantially greater than the natural background incidence of the condition. In people receiving bisphosphonates to treat osteoporosis, incidence estimates range from less than 0.1 to 0.7 cases per 10,000 patient years of exposure (<a href="./references#CD012432-bbs2-0054" title="Chamizo CarmonaE , Gallego FloresA , Loza SantamaríaE , Herrero OleaA , Rosario LozanoMP . Systematic literature review of bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis. Reumatología Clinica2013;9(3):172-7. [DOI: 10.1016/j.reuma.2012.05.005] [PMID: 22784630]">Chamizo Carmona 2013</a>; <a href="./references#CD012432-bbs2-0075" title="GrbicJT , BlackDM , LylesKW , ReidDM , OrwollE , McClungM , et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. Journal of the American Dental Association2010;141(11):1365-70. [PMID: 21037195]">Grbic 2010</a>). In a recent report studying people exposed to denosumab for treatment of osteoporosis, the incidence of MRONJ was 5.2 per 10,000 patient‐years (<a href="./references#CD012432-bbs2-0051" title="BoneHG , WagmanRB , BrandiML , BrownJP , ChapurlatR , CummingsSR , et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. lancet. Diabetes &amp; Endocrinology2017;5(7):513-23. [DOI: 10.1016/S2213-8587(17)30138-9] [PMID: 28546097]">Bone 2017</a>). The risk for MRONJ among people with osteoporosis treated with bisphosphonates or denosumab approximates the risk for MRONJ that is observed in placebo groups (<a href="./references#CD012432-bbs2-0051" title="BoneHG , WagmanRB , BrandiML , BrownJP , ChapurlatR , CummingsSR , et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. lancet. Diabetes &amp; Endocrinology2017;5(7):513-23. [DOI: 10.1016/S2213-8587(17)30138-9] [PMID: 28546097]">Bone 2017</a>; <a href="./references#CD012432-bbs2-0075" title="GrbicJT , BlackDM , LylesKW , ReidDM , OrwollE , McClungM , et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. Journal of the American Dental Association2010;141(11):1365-70. [PMID: 21037195]">Grbic 2010</a>). The risk of MRONJ among people exposed to antiresorptive medications for the treatment of osteoporosis is approximately 100‐fold smaller than the risk in people with cancer (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). </p> <p>Evidence supporting the association of antiangiogenic medications with the development of MRONJ is primarily based on case reports. The frequency of MRONJ in people receiving antiangiogenic agents is not known accurately and reliably. Analysis of the United States Food and Drug Administration’s Adverse Event Reporting System database showed that the intravenous BPs were associated with the highest risk for MRONJ, denosumab was associated with risk comparable to bisphosphonates used for osteoporosis, and the antiangiogenic agents were associated with the lowest risk for MRONJ (<a href="./references#CD012432-bbs2-0116" title="ZhangX , HamadehIS , SongS , KatzJ , MorebJS , LangaeeTY , et al. Osteonecrosis of the jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). Journal of Bone and Mineral Research2010;31(2):336-40. [DOI: 10.1002/jbmr.2693] [PMID: 26288087]">Zhang 2016</a>). In a combined analysis of three phase III trials the incidence of MRONJ in people exposed to the angiogenesis inhibitor bevacizumab was 0.2% (<a href="./references#CD012432-bbs2-0076" title="GuarneriV , MilesD , RobertN , DiérasV , GlaspyJ , SmithI , et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Research and Treatment2010;122(1):181-8. [DOI: 10.1007/s10549-010-0866-3] [PMID: 20361252]">Guarneri 2010</a>). The incidence was substantially higher in those exposed to both zoledronic acid and bevacizumab (<a href="./references#CD012432-bbs2-0076" title="GuarneriV , MilesD , RobertN , DiérasV , GlaspyJ , SmithI , et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Research and Treatment2010;122(1):181-8. [DOI: 10.1007/s10549-010-0866-3] [PMID: 20361252]">Guarneri 2010</a>). </p> <p>The treatment of MRONJ is challenging, and an effective and appropriate therapy that substantially improves the outcome remains to be identified. The median time to resolution of osteonecrosis symptoms may be up to 12 months and depends on the specific therapeutic intervention (<a href="./references#CD012432-bbs2-0081" title="HinsonAM , SiegelER , Stack BC Jr. Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis. Journal of Oral and Maxillofacial Surgery2015;73(1):53-62. [DOI: 10.1016/j.joms.2014.07.012] [PMID: 25511956]">Hinson 2015</a>). Additional information on the natural history of MRONJ comes from a report of individuals with multiple myeloma who were prospectively observed for a minimum of 3.2 years following diagnosis (<a href="./references#CD012432-bbs2-0047" title="BadrosA , TerposE , KatodritouE , GoloubevaO , KastritisE , VerrouE , et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. Journal of Clinical Oncology2008;26(36):5904-9. [DOI: 10.1200/JCO.2008.16.9300] [PMID: 19018084]">Badros 2008</a>). MRONJ resolved in 62% of cases, resolved and then recurred in 12%, and did not heal in 26%. </p> <section id="CD012432-sec-0011"> <h4 class="title">Antiresorptive medications associated with MRONJ</h4> <p>Bisphosphonates are osteotropic agents with antiresorptive activity that are used in a wide spectrum of indications such as the treatment and prevention of osteoporosis, as well as the treatment of Paget's disease, multiple myeloma, and malignancy‐associated hypercalcaemia. Bisphosphonates bind to bone hydroxyapatite and specifically inhibit the activity of osteoclasts, the bone‐resorbing cells. Bone turnover is thereby reduced, which results in an increase in the mineral density of the bone and a reduction in serum calcium (<a href="./references#CD012432-bbs2-0056" title="ChestnutC , MajumdarS , GardnerJ . Assessment of bone quality, quantity and turnover with multiple methodologies at multiple skeletal sites. Advances in Experimental Medicine and Biology2001;496:95-7.">Chestnut 2001</a>; <a href="./references#CD012432-bbs2-0077" title="GuyattGH , CranneyA , GriffithL . Summary of meta-analysis of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinology Metabolism Clinics of North America2002;31(3):659-79.">Guyatt 2002</a>; <a href="./references#CD012432-bbs2-0106" title="RuggieroSL . Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clinical Cases in Mineral and Bone Metabolism2007;4(1):37-42. [DOI: 10.1016/j.joms.2014.04.031] [PMID: 25234529]">Ruggiero 2007</a>; <a href="./references#CD012432-bbs2-0110" title="Sigua-RodriguezEA , da Costa RibeiroR , deBritoAC , Alvarez-PinzonN , deAlbergaria-BarbosaJR . Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. International Journal of Dentistry2014;2014:192320. [PMID: 24868206]">Sigua‐Rodriguez 2014</a>). Bisphosphonates have a long retention time in bone, and effects may persist for some time after treatment has been stopped. There are two major risk categories for bisphosphonate‐related ONJ: (i) low risk in individuals without cancer treated with oral bisphosphonates (e.g. alendronic acid, clodronic acid, etidronic acid, ibandronic acid, and risedronic acid), or intravenous bisphosphonates (e.g. ibandronic acid and zoledronic acid) for osteoporosis, Paget’s disease, osteopenia, and osteogenesis imperfecta; and (ii) high risk in individuals with cancer treated with intravenous bisphosphonates (e.g. zoledronic acid, pamidronic acid, and ibandronic acid) for multiple myeloma and bone metastases (<a href="./references#CD012432-bbs2-0048" title="BaganJ , ScullyC , SabaterV , JimenezY . Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ). A concise update. Oral Oncology2009;45(7):551–4.">Bagan 2009</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>; <a href="./references#CD012432-bbs2-0113" title="VescoviP . Bisphosphonates and osteonecrosis: an open matter. Clinical Cases in Mineral and Bone Metabolism2012;9(3):142-4. [PMID: 23289026]">Vescovi 2012a</a>). Additional parameters affecting the development of bisphosphonate‐related ONJ include the duration of bisphosphonate exposure, age, comedication, comorbidity, smoking, and oral health/oral hygiene (<a href="./references#CD012432-bbs2-0049" title="BamiasA , KastritisE , BamiaC , MoulopoulosLA , MelakopoulosI , BozasG , et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of Clinical Oncology2005;23(34):8580-7.">Bamias 2005</a>; <a href="./references#CD012432-bbs2-0063" title="DimopoulosMA , KastritisE , AnagnostopoulosA , MelakopoulosI , GikaD , MoulopoulosLA , et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica2006;91(7):968-71.">Dimopoulos 2006</a>; <a href="./references#CD012432-bbs2-0083" title="KatsarelisH , ShahNP , DhariwalDK , PazianasM . Infection and medication-related osteonecrosis of the jaw. Journal of Dental Research2015;94(4):534-9.">Katsarelis 2015</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>; <a href="./references#CD012432-bbs2-0110" title="Sigua-RodriguezEA , da Costa RibeiroR , deBritoAC , Alvarez-PinzonN , deAlbergaria-BarbosaJR . Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. International Journal of Dentistry2014;2014:192320. [PMID: 24868206]">Sigua‐Rodriguez 2014</a>). </p> <p>Denosumab, a potent antiresorptive agent, is used to treat osteoporosis in postmenopausal women and in men who have an increased risk of fracture. The recommended dose is 60 mg administered as a single subcutaneous injection once every six months. Denosumab is also used to prevent bone complications in adults with bone metastases from solid tumours and to treat a type of bone cancer called giant cell tumour of bone. The recommended maintenance dose for the latter indications is much higher, 120 mg every four weeks. Denosumab is a monoclonal antibody, which has been designed to attach to an antigen called RANK ligand (RANKL). By attaching to and blocking RANKL, denosumab reduces the formation and activity of osteoclasts, the cells in the body that are involved in breaking down bone tissue (<a href="./references#CD012432-bbs2-0083" title="KatsarelisH , ShahNP , DhariwalDK , PazianasM . Infection and medication-related osteonecrosis of the jaw. Journal of Dental Research2015;94(4):534-9.">Katsarelis 2015</a>; <a href="./references#CD012432-bbs2-0098" title="PageauSC . Denosumab. MAbs2009;1(3):210-5.">Pageau 2009</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>; <a href="./references#CD012432-bbs2-0115" title="XuSF , AdamsB , YuXC , XuM . Denosumab and giant cell tumour of bone—a review and future management considerations. Current Oncology2013;20(5):e442-7.">Xu 2013</a>). The exact pathophysiological mechanisms of denosumab‐related ONJ are currently unknown. </p> </section> <section id="CD012432-sec-0012"> <h4 class="title">Antiangiogenic medications associated with MRONJ</h4> <p>Antiangiogenic agents are increasingly used as anticancer drugs for the treatment of renal cell carcinomas, gastrointestinal tumours, and other solid tumours. The drugs interfere with the formation of new blood vessels by inhibiting angiogenesis signalling cascades, such as vascular endothelial growth factor signalling (bevacizumab and aflibercept), mechanistic target of rapamycin signalling (temsirolimus and everolimus), or receptor tyrosine kinase signalling (sunitinib). MRONJ is a known, rare side effect of these agents, possibly resulting from their interaction with wound healing or osteoclast differentiation and survival (<a href="./references#CD012432-bbs2-0099" title="PatelV , KelleherM , SproatC , KwokJ , McGurkM . New cancer therapies and jaw necrosis. British Dental Journal2015;219(5):203-7.">Patel 2015</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). Drug approval authorities (US Food and Drug Administration, European Medicines Agency) have included drug safety warnings in the drug labels of bevacizumab, aflibercept, and sunitinib regarding the risk of MRONJ. </p> </section> </section> <section id="CD012432-sec-0013"> <h3 class="title" id="CD012432-sec-0013">Description of the intervention</h3> <p>Interventions for the prevention of MRONJ in at‐risk individuals or the management of MRONJ in individuals with manifest disease may include the following. </p> <section id="CD012432-sec-0014"> <h4 class="title">Prophylaxis of MRONJ</h4> <p>A range of dental prophylactic measures may be used alone or in combination. A primary means of prevention is the completion of all dental treatment (such as restorative therapy, root canal treatment, periodontitis therapy, or tooth extraction) before the commencement of antiresorptive or antiangiogenic therapy or as soon as possible following the commencement of antiresorptive or antiangiogenic therapy to ensure that treatment is completed within the specified ‘time frame’ for the intended agent. Antibiotic prophylaxis or antiseptic mouthwash (e.g. chlorhexidine) may be used. Individuals may take part in a preventive recall programme, or be provided with information regarding antiresorptive or antiangiogenic therapy risks, professional teeth cleaning, effective oral hygiene, and the importance of limiting or ceasing oral health risk behaviours (such as smoking and drug and alcohol use), or both. Surgical interventions may use a non‐traumatic surgical technique (i.e. surgical treatment designed to minimise tissue damage). The use of plasma rich in growth factors (PRGF) may promote bone and adjacent soft tissue regeneration in post‐extraction defects, thereby reducing the risk of MRONJ. To minimise wound exposure to bacteria, reconstructive surgical techniques for wound closure can be used. Some specific dental extraction methods recommend the discontinuation of antiresorptive or antiangiogenic agents before dentoalveolar surgery. </p> </section> <section id="CD012432-sec-0015"> <h4 class="title">Treatment of MRONJ</h4> <p>For individuals with established MRONJ, the objective is to control infection, minimise necrosis progression, and promote tissue healing (<a href="./references#CD012432-bbs2-0048" title="BaganJ , ScullyC , SabaterV , JimenezY . Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ). A concise update. Oral Oncology2009;45(7):551–4.">Bagan 2009</a>; <a href="./references#CD012432-bbs2-0105" title="RollasonV , LaverrièreA , MacDonaldLC , WalshT , TramèrMR , Vogt-FerrierNB . Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD008455. [DOI: 10.1002/14651858.CD008455.pub2]">Rollason 2016</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>; <a href="./references#CD012432-bbs2-0110" title="Sigua-RodriguezEA , da Costa RibeiroR , deBritoAC , Alvarez-PinzonN , deAlbergaria-BarbosaJR . Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. International Journal of Dentistry2014;2014:192320. [PMID: 24868206]">Sigua‐Rodriguez 2014</a>; <a href="./references#CD012432-bbs2-0112" title="VescoviP , MerigoE , MeletiM , ManfrediM . Bisphosphonate-associated osteonecrosis (BON) of the jaws: a possible treatment?Journal of Oral and Maxillofacial Surgery2006;64(9):1460-2.">Vescovi 2006</a>; <a href="./references#CD012432-bbs2-0113" title="VescoviP . Bisphosphonates and osteonecrosis: an open matter. Clinical Cases in Mineral and Bone Metabolism2012;9(3):142-4. [PMID: 23289026]">Vescovi 2012a</a>). The standard medical care of MRONJ is currently anti‐infective treatment with systemic antibiotics or oral antiseptic rinses (e.g. chlorhexidine), or both, and surgical debridement or resection (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). </p> <section id="CD012432-sec-0016"> <h5 class="title">Non‐surgical treatment options</h5> <p>Healing may be stimulated by oral pentoxifylline and α‐tocopherol (vitamin E) in addition to antimicrobial therapy. Other options are adjunct hyperbaric oxygen (HBO) therapy, which involves breathing pure oxygen in a pressurised room or tube, or topical ozone therapy (OT) to improve healing. Low‐level laser therapy (LLLT) is also considered a promising adjunctive treatment method for MRONJ. The lasers most commonly used for biomodulation in bone are argon, carbon dioxide, helium/neon, and neodymium‐doped yttrium‐aluminium‐garnet. The use of (autologous) platelet‐rich plasma (PRP) has been suggested to enhance postsurgical wound healing. PRP is commonly used in a gel formulation, which is formed by mixing PRP (derived from the centrifugation of autologous whole blood) with thrombin and calcium chloride. PRP gel contains higher amounts of fibrinogen, platelets, and growth factors than whole blood. Moreover, bone may be restored by teriparatide, a recombinant form of parathyroid hormone. Teriparatide is approved for the treatment of osteoporosis but is used off‐label for other indications such as fracture healing, dental stability, and ONJ. Recombinant human bone morphogenetic proteins (rhBMPs), which also have the ability to induce osteogenesis, are another treatment option to enhance bone healing in MRONJ. After sequestrectomy, a carrier/scaffold (absorbable collagen sponge) that contains rhBMP is placed into the defect. </p> </section> <section id="CD012432-sec-0017"> <h5 class="title">Surgical treatment options</h5> <p>Surgical treatments include sequestrectomy, debridement, resection, immediate reconstruction. Surgical treatment may also include extraction of teeth within exposed necrotic bone. </p> </section> </section> </section> <section id="CD012432-sec-0018"> <h3 class="title" id="CD012432-sec-0018">How the intervention might work</h3> <section id="CD012432-sec-0019"> <h4 class="title">Prophylaxis of MRONJ</h4> <p>Controlling risk factors for MRONJ may represent an effective prophylaxis for MRONJ. MRONJ is a complication that can develop spontaneously after dentoalveolar surgery in combination with antiresorptive agents. Therefore, the completion of necessary elective dentoalveolar surgery before the start of this therapy may help reduce the risk of MRONJ (<a href="./references#CD012432-bbs2-0106" title="RuggieroSL . Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clinical Cases in Mineral and Bone Metabolism2007;4(1):37-42. [DOI: 10.1016/j.joms.2014.04.031] [PMID: 25234529]">Ruggiero 2007</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). Another known risk factor is infection (<a href="./references#CD012432-bbs2-0083" title="KatsarelisH , ShahNP , DhariwalDK , PazianasM . Infection and medication-related osteonecrosis of the jaw. Journal of Dental Research2015;94(4):534-9.">Katsarelis 2015</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). Dental prophylaxis, caries control, and conservative restorative dentistry are expected to minimise the number of bacteria and eliminate the ports of entry for bacteria, thereby reducing the risk of infection. Regular dental evaluations during antiresorptive or antiangiogenic therapy may help to recognise significant risks at an early stage and enable prompt measures to be taken to counter them (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>; <a href="./references#CD012432-bbs2-0109" title="Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw. Dundee, UK: SDCEP, 2017. http://www.sdcep.org.uk/published-guidance/medication-related-osteonecrosis-of-the-jaw/ (accessed 30 September 2017).">SDCEP 2017</a>). If surgery is necessary, for example, during bisphosphonate therapy, wound exposure to bacteria may be controlled by antibiotic prophylaxis, antiseptic mouthwash, or both. Choosing of surgical procedures that help minimise bone exposure or trauma to the jaws may reduce the risk of MRONJ. Platelet‐derived growth‐factor preparations, such as PRP and PRGF, applied at the surgical site may accelerate wound healing and reduce the time of increased infection risk. Stopping antiresorptive drugs before an invasive dental procedure (drug holiday) could be useful for the prevention of MRONJ. Due to the pharmacokinetics, the antiresorptive effect of bisphosphonates and denosumab is maintained for several weeks or months. This would require cessation of antiresorptive therapy for at least two months to significantly reduce the risk of MRONJ during invasive dental procedures (<a href="./references#CD012432-bbs2-0060" title="DammDD , JonesDM . Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. General Dentistry2013;61(5):33-8. [PMID: 23928436]">Damm 2013</a>; <a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>). </p> </section> <section id="CD012432-sec-0020"> <h4 class="title">Treatment of MRONJ</h4> <p>Treatment objectives for people with a defined diagnosis of MRONJ are to control infection of the soft and hard tissues, and minimise the progression or occurrence of bone necrosis to optimise wound healing. Stage‐dependent strategies to treat MRONJ have been proposed (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>), which can be classified into non‐surgical and surgical treatment. </p> <section id="CD012432-sec-0021"> <h5 class="title">Non‐surgical treatment options</h5> <p>Non‐surgical management includes, for example, drug treatment with teriparatide, which is a recombinant form of parathyroid hormone that stimulates osteoblasts to increase bone density when used intermittently. Alternative options are treatment with pentoxifylline and α‐tocopherol in combination with anti‐microbial therapy, OT, HBO, and LLLT (<a href="./references#CD012432-bbs2-0113" title="VescoviP . Bisphosphonates and osteonecrosis: an open matter. Clinical Cases in Mineral and Bone Metabolism2012;9(3):142-4. [PMID: 23289026]">Vescovi 2012a</a>). Pentoxifylline and α‐tocopherol have been used to treat osteoradionecrosis for many years. Pentoxifylline, a methylxanthine derivative and phosphodiesterase inhibitor, improves blood flow by increasing erythrocyte flexibility and vasodilatation, and modulates immunological activity; α‐tocopherol has antioxidant properties (<a href="./references#CD012432-bbs2-0068" title="EpsteinMS , WicknickFW , EpsteinJB , BerensonJR , GorskyM . Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology2010;110(5):593-6.">Epstein 2010</a>); pentoxifylline and α‐tocopherol may play a role in encouraging wound healing and reducing scarring; ozone has antimicrobial and wound‐healing properties, and OT as an adjunct treatment has been hypothesised to induce the repair of tissues by cleansing osteonecrotic lesions, which leads to mucosal healing (<a href="./references#CD012432-bbs2-0100" title="PetrucciMT , GallucciC , AgrilloA , MustazzaMC , FoàR . Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica2007;92(9):1289-90.">Petrucci 2007</a>; <a href="./references#CD012432-bbs2-0104" title="RipamontiCI , CislaghiE , MarianiL , ManiezzoM . Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase I-II study. Oral Oncology2011;47(3):185-90.">Ripamonti 2011</a>). HBO has been shown to be effective in addition to conventional therapies to treat osteoradionecrosis (<a href="./references#CD012432-bbs2-0050" title="BennettMH , FeldmeierJ , HampsonNB , SmeeR , MilrossC . Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD005005. [DOI: 10.1002/14651858.CD005005.pub4] [PMID: 27123955]">Bennett 2016</a>). HBO has been proven to stimulate new blood vessel growth within the damaged tissues and to improve the availability of oxygen for wound healing. Thus, HBO has been hypothesised to be a useful adjunctive treatment for MRONJ (<a href="./references#CD012432-bbs2-0070" title="FreibergerJJ . Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery2009;67(5 Suppl):96-106.">Freiberger 2009</a>). Phototherapy with a low‐intensity laser is used as an adjunctive therapy for the treatment of various diseases including wounds. The laser light used with LLLT is in the red visible and near infrared wavelength ranges and promotes biological effects, such as inflammation and angiogenesis. It also increases the inorganic matrix, which may support wound healing (<a href="./references#CD012432-bbs2-0090" title="MartinsMA , MartinsMD , LascalaCA , CuriMM , MiglioratiCA , TenisCA , et al. Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral Oncology2012;48(1):79-84.">Martins 2012</a>; <a href="./references#CD012432-bbs2-0112" title="VescoviP , MerigoE , MeletiM , ManfrediM . Bisphosphonate-associated osteonecrosis (BON) of the jaws: a possible treatment?Journal of Oral and Maxillofacial Surgery2006;64(9):1460-2.">Vescovi 2006</a>). Platelet‐derived growth‐factor preparations, such as PRP and PRGF, are applied at the surgical site as an adjuvant to stimulate regeneration of osseous and epithelial tissues, thereby accelerating wound healing. Platelet‐derived growth factors are proposed to support angiogenesis and to improve bone formation by enhancing osteoblast formation and activity (<a href="./references#CD012432-bbs2-0085" title="LeeCY , DavidT , NishimeM . Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. Journal of Oral Imlantology2007;33:371.">Lee 2007</a>; <a href="./references#CD012432-bbs2-0088" title="Lopez-JornetP , PerezAS , ArturoSP , RuiAM , AurelioT . Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review. Journal of Cranio-maxillo-facial Surgery2016;44(8):1067–72.">Lopez‐Jornet 2016</a>). rhBMP is used in surgical procedures to improve bone formation and remodelling during bone healing by enhancing the effects of osteoblast formation and activity (<a href="./references#CD012432-bbs2-0071" title="GerardDA , CarlsonER , GotcherJE , PickettDO . Early Inhibitory effects of zoledronicacid in tooth extraction sockets in dogs are negated by recombinant human bone morphogenetic protein. Journal of Oral and Maxillofacial Surgery2014;72(1):61-6.">Gerard 2014</a>). </p> </section> <section id="CD012432-sec-0022"> <h5 class="title">Surgical treatment options</h5> <p>Surgical treatments may include a more conservative approach, such as sequestrectomy and surgical debridement or aggressive therapies, such as resections of affected bone with reconstruction. One of the advantages of a more conservative surgical approach such as sequestrectomy is that a better healing can be expected because the periosteum and unaffected bone are conserved (<a href="./references#CD012432-bbs2-0066" title="EckardtAM , LemoundD , RanaM , Gellrich N-C. Surgical management of bisphosphonate-related osteonecrosis of the jaw in oncologic patients: a challenging problem. Anticancer Research2011;31:2313-8.">Eckardt 2011</a>; <a href="./references#CD012432-bbs2-0111" title="StantonDC , BalasanianE . Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. Journal of Oral and Maxillofacial Surgery2009;67:943-50.">Stanton 2009</a>; <a href="./references#CD012432-bbs2-0058" title="Comas-CalongeA , FigueiredoR , Gay-EscodaC . Surgical treatment vs. conservative treatment in intravenous bisphosphonate-related osteonecrosis of the jaws. Systematic review. Journal of cCinical and Experimental Dentistry2017;9(2):e302-e307. [DOI: 10.4317/jced.53504] [PMID: 28210453]">Comas‐Calonge 2017</a>). </p> </section> </section> </section> <section id="CD012432-sec-0023"> <h3 class="title" id="CD012432-sec-0023">Why it is important to do this review</h3> <p>Cochrane Oral Health undertook an extensive prioritisation exercise in 2014 to identify a core portfolio of titles that were the most clinically important to maintain on the Cochrane Library (<a href="./references#CD012432-bbs2-0114" title="WorthingtonH , ClarksonJ , WeldonJ . Priority oral health research identification for clinical decision-making. Evidence-Based Dentistry2015;16(3):69-71. [PMID: 26492797]">Worthington 2015</a>). This review was identified as a new priority title by the oral and maxillofacial surgery expert panel (<a href="http://ohg.cochrane.org/priority-reviews" target="_blank">Cochrane Oral Health priority review portfolio</a>). </p> <p>Among the drugs associated with MRONJ, bisphosphonates are by far the most widely used for a wide range of clinical indications. For example, bisphosphonates can be used in breast cancer and prostate cancer, which have the highest sex‐related incidence rates worldwide. Osteoporosis, another common indication for bisphosphonates, is estimated to affect 200 million women worldwide: approximately one‐tenth of women aged 60 years, one‐fifth of women aged 70 years, two‐fifths of women aged 80 years, and two‐thirds of women aged 90 years (<a href="./references#CD012432-bbs2-0082" title="KanisJA . Assessment of Osteoporosis at the Primary Health-care Level. Technical Report. Vol. 66. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases,University of Sheffield, UK, 2007.">Kanis 2007</a>). Moreover, several other drugs (denosumab, antiangiogenic medications) have recently been associated with MRONJ. MRONJ may occur as a common side effect, particularly in individuals with cancer, depending on the drug and the dosage used. Therefore, the population at risk for MRONJ is large and expanding, and the public health implications may be substantial. </p> <p>MRONJ significantly affects the quality of life (QoL), and the decline in QoL correlates with MRONJ stage (<a href="./references#CD012432-bbs2-0084" title="KyrgidisA , TriaridisS , KontosK , PatrikidouA , AndreadisC , ConstantinidisJ , et al. Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires. Anticancer Research2012;32(8):3527-34. [PMID: 22843941]">Kyrgidis 2012</a>; <a href="./references#CD012432-bbs2-0095" title="MiksadRA , LaiKC , DodsonTB , WooSB , TreisterNS , AkinyemiO , et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist2011;16(1):121-32. [DOI: 10.1634/theoncologist.2010-0183] [PMID: 21212433]">Miksad 2011</a>). The following factors contribute to impairment of QoL: (i) infected and painful necrotic jaw bone; (ii) ulcerated, painful, and swollen oral mucosa; (iii) chronic sinus tracts and facial disfigurement; (iv) impaired speech, swallowing, and eating; and (v) frequent medical and dental evaluations and treatments (<a href="./references#CD012432-bbs2-0094" title="MiglioratiCA , MattosK , PalazzoloMJ . How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care. Journal of the American Dental Association2010;141(5):562-6.">Migliorati 2010</a>). Rehabilitation after a complete cure of MRONJ is often protracted. A further aggravating circumstance is a high risk of recurrence, which is higher than in other diseases of the jaw bone. Thus, it is important to develop strategies to prevent or manage MRONJ. Preventative dentistry may be shown to decrease the incidence of MRONJ, in which case the implementation of preventive strategies will become an important consideration for individuals, clinicians, and policy makers (<a href="./references#CD012432-bbs2-0063" title="DimopoulosMA , KastritisE , AnagnostopoulosA , MelakopoulosI , GikaD , MoulopoulosLA , et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica2006;91(7):968-71.">Dimopoulos 2006</a>; <a href="./references#CD012432-bbs2-0103" title="RipamontiCI , ManiezzoM , CampaT , FagnoniE , BrunelliC , SaibeneG , et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Annals of Oncology2009;20(1):137-45. [PMID: 18647964]">Ripamonti 2009</a>). Epidemiological studies have shown that the risk of MRONJ increases with a longer duration of treatment and with higher drug doses. Effective measures to prevent and treat MRONJ may significantly improve the risk‐benefit balance, in particular for people requiring long‐term or high‐dose therapy. </p> <p>However, there is uncertainty regarding how to prevent MRONJ before and during bisphosphonate therapy and how to manage manifest MRONJ (<a href="./references#CD012432-bbs2-0087" title="Lopez-JornetP , Camacho-AlonsoF , Molina-MinanoF , Gomez-GarciaF . Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. Journal of Evaluation in Clinical Practice2010;16(5):878-82.">Lopez‐Jornet 2010</a>). As a consequence, current recommendations are contradictory in certain respects (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>; <a href="./references#CD012432-bbs2-0109" title="Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw. Dundee, UK: SDCEP, 2017. http://www.sdcep.org.uk/published-guidance/medication-related-osteonecrosis-of-the-jaw/ (accessed 30 September 2017).">SDCEP 2017</a>). This review complements and extends the previous Cochrane Review by <a href="./references#CD012432-bbs2-0105" title="RollasonV , LaverrièreA , MacDonaldLC , WalshT , TramèrMR , Vogt-FerrierNB . Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD008455. [DOI: 10.1002/14651858.CD008455.pub2]">Rollason 2016</a>, which focused on interventions for treating ONJ associated with bisphosphonate drugs. </p> <p>This review was first published in 2017 evaluating the prophylaxis and treatment of MRONJ (<a href="./references#CD012432-bbs2-0118" title="Beth‐TasdoganNH , MayerB , HusseinH , ZolkO . Interventions for managing medication‐related osteonecrosis of the jaw. Cochrane Database of Systematic Reviews2017, Issue 10. Art. No: CD012432. [DOI: 10.1002/14651858.CD012432.pub2]">Beth‐Tasdogan 2017</a>). We completed this update in 2022. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012432-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012432-sec-0024"></div> <p>To assess the effects of interventions versus no treatment, placebo, or an active control for the prophylaxis of medication‐related osteonecrosis of the jaw (MRONJ) in people exposed to antiresorptive or antiangiogenic drugs. </p> <p>To assess the effects of non‐surgical or surgical interventions (either singly or in combination) versus no treatment, placebo, or an active control for the treatment of people with manifest MRONJ. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012432-sec-0025" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012432-sec-0025"></div> <section id="CD012432-sec-0026"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012432-sec-0027"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) comparing one modality of intervention with another for the prevention or treatment of MRONJ. We excluded quasi‐randomised and non‐RCTs, as well as case studies, case series (or those of case series design), and cross‐sectional studies. We did not exclude studies on the basis of language, publication status or date of publication. </p> </section> <section id="CD012432-sec-0028"> <h4 class="title">Types of participants</h4> <p>To assess preventive strategies, we included participants who were treated with known risk medications and who had not yet developed MRONJ before assignment to the experimental or control group. </p> <p>To assess interventions to treat MRONJ, we included people who had developed clinically apparent MRONJ. Case definition included exposure to risk drug and the presence of necrotic bone or fistulas that probe to bone. </p> <p>We applied no restrictions regarding participant sex, age, initial health status, and pre‐existing conditions, or type of ONJ‐related drug (e.g. alendronic acid, clodronic acid, etidronic acid, ibandronic acid, incadronic acid, olpadronic acid, pamidronic acid, risedronic acid, tiludronic acid, zoledronic acid, denosumab, bevacizumab, aflibercept, sunitinib, temsirolimus, or everolimus), dose, or duration of therapy. To comply with the MRONJ case definition (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>), we did not include participants with a history of head and neck radiation therapy. </p> </section> <section id="CD012432-sec-0029"> <h4 class="title">Types of interventions</h4> <section id="CD012432-sec-0030"> <h5 class="title">For prophylaxis of MRONJ</h5> <p>Any intervention (before or after commencement of antiresorptive or antiangiogenic drug therapy) that aims at prevention of MRONJ. Examples of interventions discussed in the literature include the following. </p> <p> <ul id="CD012432-list-0001"> <li> <p>Completion of all necessary dental treatment before the commencement of antiresorptive or antiangiogenic agents or as soon as possible following commencement of antiresorptive or antiangiogenic agents </p> </li> <li> <p>Antibiotic prophylaxis or antiseptic mouthwash</p> </li> <li> <p>Preventive recall programme and provision of information for patients</p> </li> <li> <p>Non‐traumatic surgery (i.e. surgical treatment designed to minimise tissue damage), reconstructive techniques for wound closure to minimise wound exposure to bacteria, and specific dental extraction protocols </p> </li> <li> <p>Supportive measures to accelerate wound healing after surgery, such as platelet‐rich plasma (PRP) and plasma rich in growth factors (PRGF) </p> </li> <li> <p>Cessation of therapy with antiresorptive or antiangiogenic agents (‘drug holiday’) before invasive dental procedures </p> </li> </ul> </p> </section> <section id="CD012432-sec-0031"> <h5 class="title">For treatment of MRONJ</h5> <p>Any intervention (non‐surgical, surgical, or a combination of both) that aims to treat clinically manifest MRONJ. Examples of interventions discussed in the literature include the following. </p> <p> <ul id="CD012432-list-0002"> <li> <p>Non‐surgical</p> <ul id="CD012432-list-0003"> <li> <p>Antiseptic mouthwashes</p> </li> <li> <p>Antibiotic and antifungal therapy</p> </li> <li> <p>Parathyroid hormone and teriparatide</p> </li> <li> <p>Pentoxifylline and α‐tocopherol</p> </li> <li> <p>Ozone therapy (OT)</p> </li> <li> <p>Hyperbaric oxygen therapy (HBO)</p> </li> <li> <p>Laser therapy (low‐level laser therapy (LLLT))</p> </li> <li> <p>Platelet‐derived growth‐factor preparations, such as PRP and PRGF</p> </li> <li> <p>Recombinant human bone morphogenetic proteins (rhBMPs)</p> </li> </ul> </li> <li> <p>Surgical</p> <ul id="CD012432-list-0004"> <li> <p>Surgical debridement, sequestrectomy</p> </li> <li> <p>Jaw bone resection</p> </li> <li> <p>Extraction of teeth within exposed necrotic bone</p> </li> </ul> </li> </ul> </p> <p><b>Comparisons:</b> any single or combined experimental intervention versus control. The control arm consisted of participants receiving no treatment, placebo, or an active control (e.g. standard care). </p> </section> </section> <section id="CD012432-sec-0032"> <h4 class="title">Types of outcome measures</h4> <section id="CD012432-sec-0033"> <h5 class="title">Primary outcomes</h5> <section id="CD012432-sec-0034"> <h6 class="title">Prophylaxis of MRONJ</h6> <section id="CD012432-sec-0035"> <p><b>Incidence of MRONJ</b></p> <p>Two related measures are often used to describe the incidence of MRONJ: incidence proportion (cumulative incidence) and incidence rate of MRONJ. As the incidence rate of MRONJ peaks after two to four years of exposure to bisphosphonates or denosumab in individuals with cancer (<a href="./references#CD012432-bbs2-0078" title="HenryDH , CostaL , GoldwasserF , HirshV , HungriaV , PrausovaJ , et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology2011;29(9):1125-32. [DOI: 10.1200/JCO.2010.31.3304] [PUBMED: 21343556]">Henry 2011</a>; <a href="./references#CD012432-bbs2-0097" title="NakamuraM , UmetsuR , AbeJ , MatsuiT , UedaN , KatoY , et al. Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. Journal of Pharmaceutical Health Care and Sciences2015;22(1):34. [DOI: 10.1186/s40780-015-0035-2] [PMID: 26819745]">Nakamura 2015</a>; <a href="./references#CD012432-bbs2-0108" title="SaadF , BrownJE , Van PoznakC , IbrahimT , StemmerSM , StopeckAT , et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of Oncology2012;23(5):1341-7. [DOI: 10.1093/annonc/mdr435] [PMID: 21986094]">Saad 2012</a>), we had originally planned to include only trials with a follow‐up period of at least three years for the primary outcome. However, we found that the three‐year follow‐up threshold was not applicable as a strict selection criterion for the following reasons: a large proportion of individuals with metastatic cancer (i.e. those most likely to be affected by MRONJ) may die before reaching a three‐year follow‐up. Moreover, follow‐up periods were reported inconsistently between studies (mean follow‐up versus range, follow‐up period of the total study population versus that for each study arm separately, follow‐up per protocol versus follow‐up period as observed). </p> </section> </section> <section id="CD012432-sec-0036"> <h6 class="title">Treatment of MRONJ</h6> <section id="CD012432-sec-0037"> <p><b>Healing of MRONJ</b></p> <p>There is no standardised scale for the assessment of MRONJ healing. Healing of MRONJ may be defined based on clinical examination, imaging findings, or both. Wound healing may be defined as absolute area healed per day, percentage of initial area healed per day, and advance of the wound margin towards the wound centre per day. Wound healing may also be defined as the time taken for mucosa to completely cover necrotic tissue and exposed bone (‘cure period’). The number of participants with resolution of MRONJ (defined as mucosal healing with coverage of exposed bone) within a given time period (e.g. six months) may also be used to describe the healing of MRONJ. Follow‐up time should be at least six months for this primary outcome. </p> </section> </section> </section> <section id="CD012432-sec-0038"> <h5 class="title">Secondary outcomes</h5> <section id="CD012432-sec-0039"> <h6 class="title">Prophylaxis of MRONJ</h6> <p> <ul id="CD012432-list-0005"> <li> <p>Quality of life (QoL)</p> </li> <li> <p>Time‐to‐event</p> </li> <li> <p>Rate of complications and side effects of the intervention</p> </li> </ul> </p> </section> <section id="CD012432-sec-0040"> <h6 class="title">Treatment of MRONJ</h6> <p> <ul id="CD012432-list-0006"> <li> <p>QoL</p> </li> <li> <p>Recurrence</p> </li> <li> <p>Rate of complications and side effects of the intervention</p> </li> </ul> </p> <p>For QoL measures, we reported whether validated scales were used. Non‐validated scales were not excluded a priori. QoL had to have been measured at baseline and at least once during follow‐up. </p> <p>For the outcome 'complications', if the intervention involved interruption/delay of antiresorptive or antiangiogenic treatment or progression of the underlying disease (e.g. fracture in osteoporosis or disease progression in cancer) were considered complications of the intervention. </p> </section> </section> </section> </section> <section id="CD012432-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012432-sec-0042"> <h4 class="title">Electronic searches</h4> <p>Cochrane Oral Health’s Information Specialist conducted systematic searches in the following databases for randomised controlled trials and controlled clinical trials. Due to the Cochrane Centralised Search project to identify all clinical trials on the database and add them to CENTRAL, we only searched recent years of the Embase database. Please see the <a href="http://oralhealth.cochrane.org/how-search-studies" target="_blank">searching page on the Cochrane Oral Health website</a> for more information. We did not place any other restrictions on the language or date of publication when searching the electronic databases: </p> <p> <ul id="CD012432-list-0007"> <li> <p>Cochrane Oral Health’s Trials Register (searched 16 June 2021) (see <a href="./appendices#CD012432-sec-0134">Appendix 1</a>); </p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 5) in the Cochrane Library (searched 16 June 2021) (see <a href="./appendices#CD012432-sec-0135">Appendix 2</a>); </p> </li> <li> <p>MEDLINE Ovid (1946 to 16 June 2021) (see <a href="./appendices#CD012432-sec-0136">Appendix 3</a>); </p> </li> <li> <p>Embase Ovid (23 May 2016 to 16 June 2021) (see <a href="./appendices#CD012432-sec-0137">Appendix 4</a>). </p> </li> </ul> </p> <p>Subject strategies were modelled on the search strategy designed for MEDLINE Ovid. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategies designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in the Cochrane Handbook for Systematic Reviews of Interventions, Version 6.3, (<a href="./references#CD012432-bbs2-0086" title="LefebvreC , GlanvilleJ , BriscoeS , FeatherstoneR , LittlewoodA , MarshallC , et al. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. . Available from www.training.cochrane.org/handbook..">Lefebvre 2022</a>)). </p> </section> <section id="CD012432-sec-0043"> <h4 class="title">Searching other resources</h4> <p>The following trial registries were searched for ongoing studies:</p> <p> <ul id="CD012432-list-0008"> <li> <p>US National Institutes of Health Ongoing Trials Register (<a href="http://clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a>; searched 16 June 2021) (see <a href="./appendices#CD012432-sec-0138">Appendix 5</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>;  16 June 2021) (see <a href="./appendices#CD012432-sec-0139">Appendix 6</a>). </p> </li> </ul> </p> <p>We asked experts in the field to help identify unpublished literature and searched the reference lists of potential clinical trials in an attempt to identify any study not found by the other searches. </p> <p>We searched the reference lists of included studies and relevant systematic reviews for further studies. </p> <p>We checked that none of the included studies in this review were retracted due to error or fraud. </p> <p>We did not perform a separate search for adverse effects of interventions used, we considered adverse effects described in included studies only. </p> </section> </section> <section id="CD012432-sec-0044"> <h3 class="title" id="CD012432-sec-0044">Data collection and analysis</h3> <section id="CD012432-sec-0045"> <h4 class="title">Selection of studies</h4> <p>Two review authors (NBT (for the original and updated review) and JP) independently assessed the titles and abstracts of each paper identified by the review search strategy. We excluded only clearly irrelevant records at this stage. The search was designed to be sensitive and include controlled clinical trials; these were filtered out early in the selection process if they were not randomised. Following this, we obtained the full text of potentially relevant studies and assessed these for eligibility based on the inclusion criteria as outlined above. In the event that the two review authors could not reach a consensus, another review author (OZ (for the original and updated review)) acted as arbiter. We maintained a detailed log of study eligibility and reasons for exclusion, and recorded these in '<a href="./references#CD012432-sec-0151" title="">Characteristics of excluded studies</a>' tables. </p> </section> <section id="CD012432-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (NBT (for the original and updated review) and JP) independently collected details from the included trials using a structured form. If necessary, a third review author (OZ (for the original and updated review)) was consulted to resolve inconsistencies. We extracted the following details and entered them into '<a href="./references#CD012432-sec-0150" title="">Characteristics of included studies</a>' tables in Review Manager 5 (RevMan 5) (<a href="./references#CD012432-bbs2-0102" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> <p> <ul id="CD012432-list-0009"> <li> <p>Methods</p> <ul id="CD012432-list-0010"> <li> <p>Trial design</p> </li> <li> <p>Duration of study</p> </li> <li> <p>Sample size calculation</p> </li> <li> <p>Country of origin</p> </li> <li> <p>Year of publication</p> </li> <li> <p>Language of the original publication</p> </li> <li> <p>Category (i.e. prophylaxis or treatment of MRONJ)</p> </li> <li> <p>Funding</p> </li> <li> <p>Registration in a public trials registry</p> </li> </ul> </li> <li> <p>Participants</p> <ul id="CD012432-list-0011"> <li> <p>Number of participants</p> </li> <li> <p>Age</p> </li> <li> <p>Sex</p> </li> <li> <p>Condition treated with antiresorptive or antiangiogenic agents</p> </li> <li> <p>Inclusion criteria</p> </li> <li> <p>Exclusion criteria</p> </li> </ul> </li> <li> <p>Interventions (i.e. the type of intervention and procedural information)</p> </li> <li> <p>Outcomes</p> <ul id="CD012432-list-0012"> <li> <p>Primary outcomes</p> </li> <li> <p>Secondary outcomes</p> </li> </ul> </li> </ul> </p> <p>We planned to contact study authors to ask for further information or clarification of their data if necessary. </p> </section> <section id="CD012432-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NB and JP) independently assessed the risk of bias in the included studies according to guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012432-bbs2-0080" title="HigginsJP , Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <p>We assessed the included trials for risk of bias (high, low, or unclear) in the following key domains: </p> <p> <ul id="CD012432-list-0013"> <li> <p>random sequence generation (allocation bias);</p> </li> <li> <p>allocation concealment (allocation bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessors (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias).</p> </li> </ul> </p> <p>'Unclear’ indicates either a lack of information or uncertainty over the potential for bias. We completed a risk of bias table for each study and presented the results graphically by study and by domain for all studies. If the risk of bias was not clear because of a lack of detail in the studies, we planned to contact the study authors to request further information. </p> <p>We categorised overall risk of bias by outcome as shown in the table below.</p> <p> <div class="table" id="CD012432-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk of bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interpretation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Within a study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Across studies</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plausible bias unlikely to seriously alter the results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk of bias for all key domains</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most information is from studies at low risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plausible bias that raises some doubt about the results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear risk of bias for one or more key domains</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most information is from studies at low or unclear risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plausible bias that seriously weakens confidence in the results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk of bias for one or more key domains</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The proportion of information from studies at high risk of bias is sufficient to affect the interpretation of results </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD012432-sec-0048"> <h4 class="title">Measures of treatment effect</h4> <p>We used RevMan 5 (<a href="./references#CD012432-bbs2-0102" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) to perform the analyses. </p> <p>For continuous data, we planned to calculate the mean differences (MDS)and 95% confidence intervals (CIs). We planned to report continuous outcomes as means and standard deviations (SDs). When studies used different instruments to measure the same construct, we planned to use the standardised difference i(SMD) n means in the analysis to combine the data. </p> <p>For dichotomous outcomes, we calculated risk ratios (RRs) along with 95% CIs from cumulative incidence data. In cases of reported incidence rates, the rate ratio was the effect measure of choice. In cases when no events are observed in one or both groups, RevMan automatically checks for problematic zero counts, and add a fixed value to all cells of a table where the problems occur. Studies with no events in either arm are excluded from the meta‐analysis of risk ratios (<a href="./references#CD012432-bbs2-0080" title="HigginsJP , Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <p>To summarise time‐to‐event data, we planned to use methods of survival analysis and we planned to express the intervention effect as a hazard ratio (HR), along with 95% CI. </p> <p>Where insufficient information was reported to enable effect measures to be calculated, we provided a narrative report of the summary measures. </p> </section> <section id="CD012432-sec-0049"> <h4 class="title">Unit of analysis issues</h4> <p>The individual participant was the unit of analysis.</p> <p>If there was a choice of time points for a primary outcome, we selected the time point closest to three years for prophylaxis and one year for treatment. We avoided multiple testing of the effect at each of the time points. </p> </section> <section id="CD012432-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>We attempted, where feasible, to contact authors from the primary studies to obtain missing data. We used the methods outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to estimate the missing standard error of the log rate ratio (<a href="./references#CD012432-bbs2-0080" title="HigginsJP , Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD012432-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>To identify and measure the statistical heterogeneity of the data, we planned to use the I² statistic (<a href="./references#CD012432-bbs2-0079" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). This value (percentage) defines the variability in effect estimates between studies that is beyond what would be expected by chance. The I² value can be categorised as not important heterogeneity (0% to 40%), moderate heterogeneity (30% to 60%), substantial heterogeneity (50% to 90%), and very substantial heterogeneity (75% to 100%) (<a href="./references#CD012432-bbs2-0079" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We also planned to use graphical displays, such as Galbraith plots, if appropriate. Galbraith plots enable the display of several estimates of the same quantity having different standard errors; this is why they provide a useful way of checking for the presence of heterogeneity (<a href="./references#CD012432-bbs2-0046" title="Anzures-CabreraJ , HigginsJP . Graphical displays for meta-analysis: an overview with suggestions for practice. Research Synthesis Methods2010;1(1):66-80. [DOI: 10.1002/jrsm.6] [PMID: 26056093]">Anzures‐Cabrera 2010</a>; <a href="./references#CD012432-bbs2-0059" title="CopasJ , Lozada-CanC . The radial plot in meta-analysis: approximations and applications. Journal of the Royal Statistical Society: Series C (Applied Statistics)2009;58(3):329-44. [DOI: 10.1111/j.1467-9876.2008.00650.x]">Copas 2009</a>). Clinical diversity (i.e. variability in the participants, interventions, and outcomes studied) may contribute to statistical heterogeneity. If a sufficient number of studies was included, we planned to explore heterogeneity by conducting subgroup analyses. If there was substantial evidence for between‐study heterogeneity, we planned to use a random‐effects meta‐analysis. </p> </section> <section id="CD012432-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>If there had been sufficient studies, we would have assessed publication bias using methods based on a funnel plot, such as Egger's test (<a href="./references#CD012432-bbs2-0067" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). However, all publication bias methods were characterised by a relatively low power and could not be assumed to prove or exclude publication bias (<a href="./references#CD012432-bbs2-0080" title="HigginsJP , Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD012432-sec-0053"> <h4 class="title">Data synthesis</h4> <p>We followed the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for the statistical analysis of results (<a href="./references#CD012432-bbs2-0080" title="HigginsJP , Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). If the studies had been sufficiently similar with respect to the participants included, interventions compared, and outcomes and time points reported, we would have conducted meta‐analyses. We would have used a random‐effects or fixed‐effect meta‐analysis as appropriate to combine quantitative data. For comparisons in which a meta‐analysis could not be carried out, we have provided a narrative report of the summary measures and treatment effects. </p> </section> <section id="CD012432-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Clinical heterogeneity (i.e. differences associated with the participants, interventions, or outcomes across the included studies) may contribute to statistical heterogeneity (i.e. differences in the effects of interventions). If a sufficient number of studies were included, we planned to explore heterogeneity by conducting subgroup analyses in any case (i.e. whether statistical heterogeneity was present or not). To assess the effect of particular aspects of the studies on the primary and secondary outcome variables, we had planned to conduct the following subgroup analyses: medication dose or dose intensity (i.e. unit dose of medication administered per unit time); medication type (e.g. nitrogenous or non‐nitrogenous bisphosphonate) or compound; stage and type of disease (e.g. cancer or non‐cancer); and risk factors (e.g. multimorbidity, age, smoker). If we had included at least 10 studies, we would have investigated these effects using a meta‐regression analysis. </p> <p>In the case of significant statistical heterogeneity, we would have attempted to identify the source of the heterogeneity with subgroup analyses. </p> </section> <section id="CD012432-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>If there had been sufficient RCTs for meta‐analyses, we would have performed a sensitivity analysis to check the robustness of results when omitting studies with high or unclear risk of bias or to investigate whether the meta‐analysis result was heavily determined by outlier studies. We would have used the Galbraith plot to detect potential outliers. </p> </section> <section id="CD012432-sec-0056"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We have developed a summary of findings table for each comparison, and have presented summary information for the primary outcomes. </p> <p>Following GRADE methods and using GRADEPro software (<a href="./references#CD012432-bbs2-0074" title="GRADEpro. Version 3.6. Hamilton (ON): GRADE Working Group, McMaster University, 2014.">GRADEPro 2014</a>), two review authors (NB and OZ) assessed the certainty of evidence with reference to the overall risk of bias of the included studies, directness of the evidence, consistency of the results, precision of the estimates, and risk of publication bias. Factors that may lead to downgrading of evidence in the GRADE approach are: (a) risk of bias, (b) inconsistency between studies, (c) indirectness, (d) imprecision, and (e) likely publication bias. We assessed the certainty of the body of evidence for each comparison and outcome as high, moderate, low, or very low. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012432-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012432-sec-0057"></div> <section id="CD012432-sec-0058"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD012432-sec-0150" title="">Characteristics of included studies</a>; <a href="./references#CD012432-sec-0151" title="">Characteristics of excluded studies</a>; <a href="./references#CD012432-sec-0152" title="">Characteristics of ongoing studies</a>. </p> <section id="CD012432-sec-0059"> <h4 class="title">Results of the search</h4> <p>We brought forward five included studies (eight references), 11 excluded studies and four ongoing studies from the previous version of the review. For details of the study selection process for the previous version of the review, see <a href="#CD012432-tbl-0013">Table 2</a>. </p> <div class="table" id="CD012432-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Previous searches</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The initial electronic search of 2016 retrieved 1105 references after de‐duplication. After screening the titles and abstracts, we excluded all but 23 references from further evaluation. We examined the full text of the remaining 23 articles and found that eight references relating to five studies met the prespecified inclusion criteria and were therefore included in this review. We identified four additional studies that are ongoing and listed these under <a href="./references#CD012432-sec-0152" title="">Characteristics of ongoing studies</a>. We excluded 11 full‐text articles for reasons noted in the <a href="./references#CD012432-sec-0151" title="">Characteristics of excluded studies</a> table. </p> </td> </tr> </tbody> </table> </div> <p>Our searches for the update identified a total of 1047 references. After de‐duplication, two review authors NBT (for the original and updated review) and JP screened the remaining 728 references as titles and abstracts, most of which did not fulfil the inclusion criteria. Twenty‐nine articles were selected for further evaluation in full text. We excluded nine ineligible articles (see <a href="./references#CD012432-sec-0151" title="">Characteristics of excluded studies</a>), and there were nine ongoing studies (see <a href="./references#CD012432-sec-0152" title="">Characteristics of ongoing studies</a>). We identified eight new RCTs (11 references) for inclusion (see <a href="./references#CD012432-bbs1-0001" title="">Included studies</a>).  </p> <p>The flow diagram summarises the study selection process for the whole review (<a href="#CD012432-fig-0001">Figure 1</a>).  </p> <div class="figure" id="CD012432-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD012432-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD012432-sec-0060"> <h4 class="title">Included studies</h4> <p>We included 13 studies in the review: five studies from the previous review (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>; <a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>; <a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>; <a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>; <a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>) and eight additional RCTs identified for this update (<a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>; <a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>; <a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>; <a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>). Five studies focused on the prophylaxis of MRONJ (<a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>; <a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>; <a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>), and eight trials investigated options for the treatment of MRONJ (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>; <a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>; <a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>; <a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>; <a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a>; <a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>; <a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>). The trials varied in sample size between 13 (<a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>) and 700 participants (<a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>). In total, 1668 participants were included in this review. More women than men took part in the studies, with the exception of one study (<a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>), which recruited only men with prostate cancer. Full details of the studies are in the <a href="./references#CD012432-sec-0150" title="">Characteristics of included studies</a> tables.  </p> <section id="CD012432-sec-0061"> <h5 class="title">Prophylaxis of MRONJ</h5> <section id="CD012432-sec-0062"> <h6 class="title">Characteristics of the trial designs and settings </h6> <p>Of the five studies concerning prophylaxis of MRONJ, three were conducted in Germany (<a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>), and two in Italy (<a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>; <a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>). All of the five studies used a parallel‐group design and had two treatment arms. </p> </section> <section id="CD012432-sec-0063"> <h6 class="title">Characteristics of the participants</h6> <p>The five studies focusing on prophylaxis of MRONJ involved a total of 1366 participants, ranging from 77 to 700 participants per study. All participants were scheduled for tooth extraction while receiving intravenous bisphosphonate for the treatment of cancer (<a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>; <a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>), or oral bisphosphonate or subcutaneous denosumab for the treatment of osteoporosis (<a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>), cancer (<a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>), or rheumatoid arthritis and Paget's disease (<a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>). </p> </section> <section id="CD012432-sec-0064"> <h6 class="title">Characteristics of the interventions</h6> <p>The following interventions were used in the included studies.</p> <p> <ul id="CD012432-list-0014"> <li> <p>Dental examinations at three‐month intervals and preventive treatments versus standard care (<a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>). </p> </li> <li> <p>Dental extraction protocol with plasma rich in growth factors (PRGF), which was inserted into the postextraction alveolus versus standard dental extraction protocol without PRGF. All participants had a professional oral hygiene session one week before surgery and antibiotics for six days starting the evening before surgery. Surgical care included anaesthesia by alveolar nerve block, no intraligamentous or intrapapillary infiltrations, mucosal flap, and suturing to enable healing via primary intention (<a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>). </p> </li> <li> <p>Surgical extractions carried out via an intrasulcular incision and mobilisation of a mucoperiosteal flap versus extractions carried out without detachment of full‐thickness flaps, and sockets were filled with absorbable haemostatic gelatine sponges (<a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>). </p> </li> <li> <p>Primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet‐rich fibrin (PRF) without subsequent primary closure. Bisphosphonate or denosumab drug holiday prior to the tooth extraction was not required. All patients received perioperative intravenous antibiotic therapy, initiated one day before surgery and continued until one day after surgery. Prior to the extraction, all patients rinsed their mouths with chlorhexidine solution. Postoperatively, patients were instructed to consume a soft diet, to apply daily mouth rinses with chlorhexidine solution, and to refrain from wearing dentures until complete mucosal healing was achieved (<a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>). </p> </li> <li> <p>Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction. All patients were pre‐treated with oral antibiotics from the week before surgery until one week after surgery and used an antimicrobial mouth rinse with chlorhexidine three times daily, starting two days before surgery and for at least five days after surgery. If a drug holiday was possible from an oncologic/osteologic perspective, antiresorptive therapy was discontinued one month before surgery until one month after surgery (<a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>). </p> </li> </ul> </p> </section> <section id="CD012432-sec-0065"> <h6 class="title">Characteristics of the outcomes </h6> <section id="CD012432-sec-0066"> <p><b>Primary outcome </b></p> <p>The primary outcome was the development of MRONJ. The major diagnostic criterion of MRONJ was non‐healing exposed bone in the mandible or maxilla for longer than eight weeks (according to the AAOMS criteria) after surgery (<a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>). <a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a> defined the success rate as the proportion of participants without clinical signs of postoperative MRONJ, such as pain, swelling, and non‐healing exposed necrotic bone or fistulas, or both, with connection to the bone. <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>) defined the primary outcome as complete mucosal coverage at the extraction site at the follow‐up examination 90 days postoperatively. <a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a> determined the incidence of MRONJ calculated as the incidence rate (i.e. the number of people developing MRONJ per patient‐years) and incidence proportion (i.e. the number of people developing MRONJ relative to the number of people in the study group. </p> </section> <section id="CD012432-sec-0067"> <p><b>Secondary outcome </b></p> <p>Intraoperative and postoperative complications were reported as secondary outcomes (<a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>). Quality of life was not investigated, except for one study that used the QoL EQ‐5D score sheet as one of the secondary study outcomes (<a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>). </p> </section> </section> </section> <section id="CD012432-sec-0068"> <h5 class="title">Treatment of MRONJ</h5> <section id="CD012432-sec-0069"> <h6 class="title">Characteristics of the trial designs and settings </h6> <p>The eight included studies concerning treatment and healing of MRONJ were conducted in the USA (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>), in Germany (<a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>), in Korea (<a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a>), two in Italy (<a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>; <a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>), in Japan (<a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>), in Australia (<a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>), and in Turkey (<a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>). </p> <p>All of the eight studies used a parallel‐group design and had two treatment arms.</p> </section> <section id="CD012432-sec-0070"> <h6 class="title">Characteristics of the participants</h6> <p>The eight studies focusing on treatment of MRONJ involved a total of 302 participants ranging from 13 to 55 participants per study. All had MRONJ related to the use of antiresorptive drugs (bisphosphonates or denosumab), mainly for the treatment of cancer or osteoporosis. </p> </section> <section id="CD012432-sec-0071"> <h6 class="title">Characteristics of the interventions</h6> <p>The interventions used in the included studies included the following.</p> <p> <ul id="CD012432-list-0015"> <li> <p>Standard care with hyperbaric oxygen (HBO) versus standard care without HBO. Treatment for MRONJ included surgical debridement at the discretion of the referring surgeon and antibiotics for any sign of local infection. Participants in the HBO group received 40 HBO sessions at 2 atmospheres of pressure for two hours each over four weeks (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>). </p> </li> <li> <p>Preoperative treatment with doxycycline, which is incorporated into viable bone and is visualised with a certified medical lamp intraoperatively versus treatment with ampicillin/sulbactam (or clindamycin in case of hypersensitivity to penicillin or a penicillin allergy) preoperatively without doxycycline labelling. Autofluorescence of vital bone, which was induced with a special fluorescence lamp (provided for the study by the manufacturer), was used to visualise vital bone intraoperatively (<a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>). </p> </li> <li> <p>Single application of leukocyte rich and platelet‐rich fibrin (L‐PRF group) versus combined application of L‐PRF and recombinant human bone morphogenetic protein 2 (rhBMP‐2) (PRF plus BMP group) after surgical removal of bone sequestra and before primary wound closure. All patients received antibiotics, analgesics, 0.12% chlorhexidine for daily rinsing, and professional dental prophylaxis in the week before surgery. Postoperatively, all patients were treated with an antibacterial mouth rinse until complete healing and with intravenous antibiotics for one week and oral antibiotics for another two weeks. (<a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a>). </p> </li> <li> <p>Autofluorescence‐guided surgery (AF) versus the traditionally treated group (non‐AF). In the AF group resection margins were visualised using the VELscope which reveals natural autofluorescence of healthy bone by emitting high‐intensity polarised ultraviolet light. In the non‐AF group, bone resection margins of patients were removed by the surgeon according his surgical experience. Absorbable sutures were used in all patients for tension‐free wound closure, and antibiotics started three days preoperatively were continued until seven days postoperatively (<a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>). </p> </li> <li> <p>Removal of necrotic bone and treatment with local application of platelet‐rich fibrin (PRF) at the surgical site before primary wound closure (tension‐free with absorbable suture material) versus removal of necrotic bone and primary wound closure without treatment with PRF. Starting three days before surgery, each patient was treated with antibiotics for 10 days. All patients also received a professional oral hygiene session and a mouth rinse with 0.2% chlorhexidine one week before surgery (<a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>). </p> </li> <li> <p>Removal of necrotic bone and treatment with local application of concentrated growth factor (CGF) at the surgical site before primary wound closure versus removal of necrotic bone and primary wound closure without treatment with CGF (<a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>). </p> </li> <li> <p>Eight weeks of subcutaneous teriparatide (TPTD) (20 mg/day) injections versus placebo injections. All participants received calcium and vitamin D supplementation and standard clinical care (<a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>). </p> </li> <li> <p>Injections of 1×/week 56.5‐μg TPTD for six months versus 20‐μg TPTD injections daily for six months. Participants in both groups received conventional therapy and intensive antibiotic therapy as needed (<a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>). </p> </li> </ul> </p> </section> <section id="CD012432-sec-0072"> <h6 class="title">Characteristics of the outcomes </h6> <section id="CD012432-sec-0073"> <p><b>Primary outcome </b></p> <p>The primary outcome was success rate, defined as the absence of a MRONJ site after surgery i.e. full mucosal coverage or the absence of exposed necrotic bone with full coverage at eight weeks after surgery (according to the AAOMS criteria) (<a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>). Giudice and colleagues defined primary outcome as mucosal integrity at six months postoperatively (<a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>; <a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>). For the primary outcome, oral lesions were scored by size and number, and a change in lesion scores compared with the baseline condition was used to grade the primary outcome. Possible outcome categories were healed (defined as gingival coverage with no exposed bone), improved, unchanged, or worse (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>).  <a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a> categorised healing outcomes as complete healing, delayed healing or no resolution at four and 16 weeks post‐surgery. <a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a> defined the outcome as change in MRONJ stage, changes in bone metabolism (bone scintigraphy), the percentage of bone formation (axial and coronal computed tomography (CT) images of the maximum osteolysis area), and bone turnover markers (osteocalcin, procollagen type I N‐terminal propeptide, bone‐specific alkaline phosphatases, urinary cross‐linked N‐telopeptide of type I collagen, urinary deoxypiridinolin, and tartrate‐resistant acid phosphatase‐5b). </p> </section> <section id="CD012432-sec-0074"> <p><b>Secondary outcomes </b></p> <p>Secondary outcomes were quality of life (QoL), laboratory measures of bone turnover, and molecular indicators of osteoclast activation, such as RANK, RANKL, OPG, and pAKt (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>), or osteoblastic responses as measured biochemically and radiologically (<a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>).  <a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a> analysed serum concentration of C‐terminal cross‐linked telopeptide of type I collagen (sCTX) of each patient with MRONJ additionally to the primary outcomes. Two studies reported mucosal integrity or full coverage at the remaining measurement time points, no signs of infection (<a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>), loss of sensitivity (numbness) of the alveolar nerve, and subjective pain as secondary outcomes (<a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>). </p> </section> </section> </section> </section> <section id="CD012432-sec-0075"> <h4 class="title">Excluded studies</h4> <p>We excluded 20 studies (11 in the last version of the review and nine from the updated searches). They were all excluded because they were not RCTs (<a href="./references#CD012432-bbs2-0014" title="AsakaT , OhgaN , YamazakiY , SatoJ , SatohC , KitagawaY . Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clinical Oral Investigations2017;21(7):2165-72. [DOI: 10.1007/s00784-016-2004-z]">Asaka 2017</a>; <a href="./references#CD012432-bbs2-0015" title="BonacinaR , MarianiU , VillaF , VillaA . Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. Journal of the Canadian Dental Association2011;77:b147. ">Bonacina 2011</a>; <a href="./references#CD012432-bbs2-0016" title="BramatiA , GirelliS , FarinaG , DazzaniMC , TorriV , MorettiA , et al. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. Journal of Bone and Mineral Metabolism2015;33(1):119-24. ">Bramati 2015</a>; <a href="./references#CD012432-bbs2-0017" title="CalvaniF , CutoneA , LepantoMS , RosaL , ValentiniV , ValentiP . Efficacy of bovine lactoferrin in the post-surgical treatment of patients suffering from bisphosphonate-related osteonecrosis of the jaws: an open-label study. Biometals2018;31(3):445-55. [DOI: 10.1007/s10534-018-0081-y] [PMID: 29435826]">Calvani 2018</a>; <a href="./references#CD012432-bbs2-0018" title="ColapintoG , VolpiR , ForinoG , TricaricoV , De BenedittisM , CortelazziR , et al. Patients' osteometabolic control improves the management of medication-related osteonecrosis of the jaw. Oral Surgery, Oral Medicine Oral Pathology and Oral Radiology2018;125(2):147-56. [DOI: 10.1016/j.oooo.2017.10.015] [PMID: 29249520]">Colapinto 2018</a>; <a href="./references#CD012432-bbs2-0019" title="CovielloV , PelusoF , DehkharganiSZ , VerdugoF , RaffaelliL , ManiconePF , et al. Platelet-rich plasma improves wound healing in multiple myeloma bisphosphonate-associated osteonecrosis of the jaw patients. Journal of Biological Regulators and Homeostatic Agents2012;26(1):151-5. ">Coviello 2012</a>; <a href="./references#CD012432-bbs2-0020" title="DE IuliisF , TaglieriL , AmorosoL , VendittozziS , BlasiL , SalernoG , et al. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Anticancer Research2014;34(5):2477-80. ">DE Iuliis 2014</a>; <a href="./references#CD012432-bbs2-0021" title="DimopoulosMA , KastritisE , BamiaC , MelakopoulosI , GikaD , RoussouM , et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology2009;20(1):117-20. ">Dimopoulos 2009</a>; <a href="./references#CD012432-bbs2-0022" title="Garcia-MartinezL , Martin-PayoR , Pelaz-GarciaA , Sierra-VegaM , Junquera-GutierrezLM . Intervention to improve awareness of the risk factors for osteonecrosis of the jaw in patients under treatment with bisphosponates. Randomised clinical trial [Intervención para la mejora del conocimiento de los factores de riesgo para el desarrollo de osteonecrosis maxilar en pacientes a tratamiento con bisfosfonatos. Ensayo clínico aleatorizado]. Enfermeria Clinica2017;27(6):352-60. [DOI: 10.1016/j.enfcli.2017.04.001] [PMID: 28583834]">Garcia‐Martinez 2017</a>; <a href="./references#CD012432-bbs2-0023" title="GiovannacciI , MeletiM , ManfrediM , MerigoE , FornainiC , BonaniniM , VescoviP . Autofluorescence as indicator for detecting the surgical margins of medication-related osteonecrosis of the jaws. Minerva stomatologica2016;65(4):248-52. [PMID: 27012287]">Giovannacci 2016</a>; <a href="./references#CD012432-bbs2-0024" title="JungJ , YooHY , LeeJW , LeeYA , KimDY , KwonYD . Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study. Journal of Bone and Miner Research2017;32(12):2445-52. [DOI: 10.1002/jbmr.3237] [PMID: 28815779 ]">Jung 2017</a>; <a href="./references#CD012432-bbs2-0025" title="LeeLW , HsiaoSH , ChenLK . Clinical treatment outcomes for 40 patients with bisphosphonates-related osteonecrosis of the jaws. Journal of the Formosan Medical Association2014;113(3):166–72. ">Lee 2014</a>; <a href="./references#CD012432-bbs2-0026" title="MontebugnoliL , FelicettiL , FelicettiL , GissiDB , PizzigalloA , PelliccioniGA , et al. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2007;104(4):473-7. ">Montebugnoli 2007</a>; <a href="./references#CD012432-bbs2-0027" title="Nica DF , RivisM , RoiCI , TodeaCD , DumaVF , SinescuC . Complementarity of photo-biomodulation, surgical treatment, and antibiotherapy for Medication-Related Osteonecrosis of the Jaws (MRONJ). Medicina (Kaunas, Lithuania) 2021 February;57(2):145. [DOI: 10.3390/medicina57020145] [PMC7914693] [PMID: 33562600]">Nica 2021</a>; <a href="./references#CD012432-bbs2-0028" title="PelazA , JunqueraL , GallegoL , García-ConsuegraL , JunqueraS , GómezC . Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide. Medicina Oral, Patologia Oral y Cirugia Bucal2014;19(4):e320–6. ">Pelaz 2014</a>; <a href="./references#CD012432-bbs2-0029" title="RodriguezAC , SilvaCE , CostaDM , MartinsM , OliveiraV , NetoRM , et al. Low level laser therapy as coadjuvant in bisphosphonate related osteonecrosis of the jaws: a pilot study. International Journal of Oral &amp; Maxillofacial Surgery2019;48(Supplement 1):103. [DOI: 10.1016/j.ijom.2019.03.314]">Rodriguez 2019</a>; <a href="./references#CD012432-bbs2-0030" title="SzentpeteriS , SchmidtL , RestarL , CsakiG , SzaboG , Vaszilko M. The effect of platelet-rich fibrin membrane in surgical therapy of medication-related osteonecrosis of the jaw. Journal of Oral and Maxillofacial Surgery 2020 May;78(5):738-48. ">Szentpeteri 2020</a>; <a href="./references#CD012432-bbs2-0031" title="VescoviP , ManfrediM , MerigoE , MeletiM , FornainiC , RoccaJP , et al. Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers in Medical Science2010;25(1):101–13. ">Vescovi 2010</a>; <a href="./references#CD012432-bbs2-0032" title="VescoviP , MerigoE , MeletiM , ManfrediM , FornainiC , NammourS . Surgical approach and laser applications in BRONJ osteoporotic and cancer patients. Journal of Osteoporosis2012;2012:Article ID 585434, 8 pages. [DOI: 10.1155/2012/585434]">Vescovi 2012</a>; <a href="./references#CD012432-bbs2-0033" title="WatanabeT , AsaiK , FukuharaS , UozumiR , BesshoK . Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: a subgroup analysis by disease stage. PLOS One [electronic resource] 2021 January;16(1):e0244859. [DOI: 10.1371/journal.pone.0244859] [PMC7781475] [PMID: 33395446]">Watanabe 2021</a>). See the <a href="./references#CD012432-sec-0151" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD012432-sec-0076"> <h4 class="title">Ongoing studies</h4> <p>There are 12 RCTs currently in process that may be included in future iterations of this review (<a href="./references#CD012432-bbs2-0034" title="Clinical study of modified curettage for medication-related osteonecrosis of the jaw. www.chictr.org.cn/showproj.aspx?proj=45608 11 November 2019. [CHICTR: ChiCTR1900027382]">ChiCTR1900027382</a>; <a href="./references#CD012432-bbs2-0035" title="DRKS00012888. Treatment strategies for medication-related osteonecrosis of the jaw - a prospective, partially randomized patient preference trial [Vergleich der chirurgischen und nicht-chirurgischen Therapie bei Patienten mit medikamenten-assoziierter Kiefernekrose – Eine prospektive, partiell randomisierte, Patientenpräferenz-Studie]. www.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00012888 (first received 17 May 2018). [DRKS: DRKS00012888]">DRKS00012888</a>; <a href="./references#CD012432-bbs2-0036" title="jRCTs071200006. Investigation of the preventive effects of antimicrobial penetrated collargen plug(TERUPLUG) for post-extraction tooth socket for osteonecrosis of the jaw after tooth extraction in patients using high-dose antiresorptive agent [sic]. rctportal.niph.go.jp/en/detail?trial_id=jRCTs071200006 (first received 20 April 2020). ">jRCTs071200006</a>; <a href="./references#CD012432-bbs2-0037" title="NCT01526915. Assessment of platelet rich fibrin efficiency on healing delay and on jawbone osteochemonecrosis provoked by bisphosphonates (OCN/PRF). clinicaltrials.gov/ct2/show/record/NCT01526915 (first received 31 January 2012). ">NCT01526915</a>; <a href="./references#CD012432-bbs2-0038" title="NCT02198001. Prospective randomized study: assessment of PRF efficacy in prevention of jaw osteonecrosis after tooth extraction (PRF). clinicaltrials.gov/ct2/show/record/NCT02198001 (first received 15 July 2014). ">NCT02198001</a>; <a href="./references#CD012432-bbs2-0039" title="Pentoxifylline and Tocopherol (PENTO) in the treatment of Medication-related Osteonecrosis of the Jaw (MRONJ). clinicaltrials.gov/show/nct03040778 February 2, 2017. ">NCT03040778</a>; <a href="./references#CD012432-bbs2-0040" title="NCT03269214. Use of topical phenytoin in bisphosphonate-related osteonecrosis of the mandible. clinicaltrials.gov/ct2/show/NCT03269214 August 31, 2017. ">NCT03269214</a>; <a href="./references#CD012432-bbs2-0041" title="Plasma rich in growth factors for treatment of medication related osteonecrosis of the jaw. clinicaltrials.gov/show/nct03390777 January 4, 2018 . [CLINICALTRIALS.GOV: NCT03390777]">NCT03390777</a>; <a href="./references#CD012432-bbs2-0042" title="NCT04512638. Best Treatment Choice for Osteonecrosis of the Jaw (BETCON). clinicaltrials.gov/ct2/show/NCT04512638 (first received 13 August 2020). ">NCT04512638</a>; <a href="./references#CD012432-bbs2-0043" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). ">NCT04531800</a>; <a href="./references#CD012432-bbs2-0044" title="Study to the effect of teriparatide formulation Forteo versus Teribon on bisphosphonate-related osteonecrosis of the jaw in osteoporosis patients. upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000010706&amp;language=E (first received 17 October 2012). ">UMIN000009132</a>; <a href="./references#CD012432-bbs2-0045" title="The clinical effect of teriparatide on BRONJ (bisphosphonate-related osteonecrosis of the jaw). https://rctportal.niph.go.jp/en/detail?trial_id=UMIN000042862 27/12/2020. [UMIN-CTR: UMIN000042862]">UMIN000042862</a>). See <a href="./references#CD012432-sec-0152" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD012432-sec-0077"> <h3 class="title">Risk of bias in included studies</h3> <p>See below and the <a href="./references#CD012432-sec-0150" title="">Characteristics of included studies</a> tables for more details about our risk of bias assessments. A graphical overview is provided in <a href="#CD012432-fig-0002">Figure 2</a>.  </p> <div class="figure" id="CD012432-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012432-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD012432-sec-0078"> <h4 class="title">Allocation</h4> <p>In all 13 trials, participants were randomly divided into two groups. The method of random sequence generation was noted in only two studies: participants were assigned by a computer randomisation programme, and we judged the risk of bias to be low (<a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>). The authors of 10 trials did not mention the generation of the randomisation sequence and we therefore rated the level of risk as unclear (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>; <a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>; <a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>; <a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>; <a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>; <a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>; <a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>). In <a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>, participants were assigned to one of two groups by an independent resident senior, which we considered to be high risk of bias.  </p> <p>We considered the use of sealed envelopes in three studies put them at low risk of bias due to inadequate allocation concealment (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>; <a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>). Allocation concealment was not reported for 10 studies, so we categorised the risk level as unclear (<a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>; <a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>; <a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>; <a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>; <a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>; <a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>; <a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>).  </p> <p>Combining these possible sources of selection bias, we therefore judged only one study to be at low risk of selection bias (<a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>), with one at high risk (<a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>), and the rest unclear.  </p> </section> <section id="CD012432-sec-0079"> <h4 class="title">Blinding</h4> <section id="CD012432-sec-0080"> <h5 class="title">Performance bias</h5> <p>We considered the level of risk for performance bias to be high in all but one of study (<a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>) because personnel were not blinded, which in many studies was due to the nature of the intervention.  </p> </section> <section id="CD012432-sec-0081"> <h5 class="title">Detection bias</h5> <p>Detection bias was rated low for three studies where outcome assessors were blinded (<a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>; <a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>). Therefore, we considered the level of risk for performance and detection bias to be high for all but one study (<a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>). </p> </section> </section> <section id="CD012432-sec-0082"> <h4 class="title">Incomplete outcome data</h4> <p>We judged attrition bias to be high in six studies (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>; <a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>; <a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>; <a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>). Although a description of losses and withdrawals was given, data analysis was performed as‐treated and not by intention‐to‐treat, or numbers of participants excluded were not balanced across intervention groups. None of the studies reported data in a format that would have enabled us to recalculate effects on an intent‐to‐treat basis. </p> <p>We judged attrition bias to be low in six studies: follow‐up was complete in five studies, with all participants included in analyses (<a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>; <a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>; <a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>), and in <a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>, although some participants were lost for the assessment of secondary endpoints; all participants were included in the assessment of the primary endpoint. </p> <p>The level of risk of attrition bias was unclear in the other two studies because completeness or loss to follow‐up was not reported (<a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>; <a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>). </p> </section> <section id="CD012432-sec-0083"> <h4 class="title">Selective reporting</h4> <p>We judged four studies to be at high risk of reporting bias (<a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>; <a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>; <a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>). In the report by <a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>, preoperative pain levels in control and intervention groups were not reported. (<a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a> presented in their publication P values of statistical analyses but did not report effect estimates of outcomes such as improvement of MRONJ. <a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a> did not report results for all follow‐up time points. <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a> did not report all outcomes; for example, quality of life survey data were missing. All of the other studies presented data for their planned outcomes and were therefore judged to be at low risk of reporting bias. </p> </section> <section id="CD012432-sec-0084"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other sources of bias. </p> </section> </section> <section id="CD012432-sec-0085"> <h3 class="title" id="CD012432-sec-0085">Effects of interventions</h3> <p>See: <a href="./full#CD012432-tbl-0001"><b>Summary of findings 1</b> Dental examinations at three‐month intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ</a>; <a href="./full#CD012432-tbl-0002"><b>Summary of findings 2</b> Dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions</a>; <a href="./full#CD012432-tbl-0003"><b>Summary of findings 3</b> Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment</a>; <a href="./full#CD012432-tbl-0004"><b>Summary of findings 4</b> Hyperbaric oxygen therapy (HBO) as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ</a>; <a href="./full#CD012432-tbl-0005"><b>Summary of findings 5</b> Autofluorescence‐guided bone surgery (experimental) compared to tetracycline fluorescence‐guided bone surgery (control) for treatment of MRONJ</a>; <a href="./full#CD012432-tbl-0006"><b>Summary of findings 6</b> Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) compared to platelet‐rich fibrin alone (control) for treatment of MRONJ</a>; <a href="./full#CD012432-tbl-0007"><b>Summary of findings 7</b> Autofluorescence‐guided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ</a>; <a href="./full#CD012432-tbl-0008"><b>Summary of findings 8</b> Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ</a>; <a href="./full#CD012432-tbl-0009"><b>Summary of findings 9</b> Concentrated growth factor and primary wound closure (experimental) versus primary wound closure only (control) for treatment of MRONJ</a>; <a href="./full#CD012432-tbl-0010"><b>Summary of findings 10</b> Teriparatide 20 μg daily (experimental) versus placebo (control) in addition to standard care for treatment of MRONJ</a>; <a href="./full#CD012432-tbl-0011"><b>Summary of findings 11</b> Teriparatide 56.5 μg weekly (experimental) versus teriparatide 20 μg daily (control) in addition to standard care for treatment of MRONJ</a> </p> <section id="CD012432-sec-0086"> <h4 class="title">Prophylaxis of MRONJ</h4> <section id="CD012432-sec-0087"> <h5 class="title">Regular dental examinations at three‐month intervals and preventive treatments versus standard care for the prophylaxis of MRONJ in men with metastatic prostate cancer and intravenous zoledronic acid </h5> <p>We identified one study with 253 participants that explored the preventive effect of a prophylactic treatment to reduce MRONJ in men with metastatic prostate cancer treated with zoledronic acid (<a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>). The study compared regular dental examinations at three‐month intervals and preventive treatments (including antibiotics before dental extractions, and the use of techniques for wound closure that avoid exposure and contamination of bone) versus standard care (i.e. monitoring and treatment if necessary at the discretion of the participant's dentist). </p> <section id="CD012432-sec-0088"> <h6 class="title">Incidence of MRONJ</h6> <p>Our primary outcome, incidence of MRONJ, was reported as incidence rate per year and incidence proportion. MRONJ was defined as the non‐healing of exposed bone in the mandible or maxilla for longer than eight weeks without any change in the stage of disease. The mean follow‐up time was 28.8 months. Regular dental examinations at three‐month intervals and preventive treatments showed a lower risk ratio (RR) for MRONJ (0.10; 95% CI 0.02 to 0.39) compared to standard care when dental extractions were performed. There was also a clinically relevant  difference in the number of MRONJ cases per patient‐years (rate ratio 0.18; 95% CI 0.04 to 0.74). We rated the certainty of the evidence for the primary outcome to be very low due to very serious risk of bias (high and unbalanced rate of cross‐overs after randomisation; high dropout rates due to high mortality; failure to adhere to the intention‐to‐treat principle; mean follow‐up differed between experimental and control groups), and very serious limitation of indirectness (all male and high‐risk patients). See <a href="./full#CD012432-tbl-0001">summary of findings Table 1</a>, <a href="./references#CD012432-fig-0003" title="">Analysis 1.1</a>, and <a href="./references#CD012432-fig-0004" title="">Analysis 1.2</a>. </p> </section> </section> <section id="CD012432-sec-0089"> <h5 class="title">Plasma rich in growth factors inserted into the postextraction alveolus in addition to standardised medical and surgical care (experimental) versus standardised medical and surgical care alone (control) for prophylaxis of MRONJ </h5> <p>One RCT reported the effect of PRGF for preventing MRONJ in 176 participants with cancer undergoing dental extractions (<a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>). </p> <section id="CD012432-sec-0090"> <h6 class="title">Incidence of MRONJ</h6> <p>The diagnosis of MRONJ was based on clinical examination and radiographic examinations. Clinical signs of MRONJ were pain, swelling, and non‐healing exposed necrotic bone or fistulas, or both, with connection to the bone. The study group had a total follow‐up period of 24 to 60 months. At the last contact, no participants in the PRGF group (N = 91) but five participants in the control group (N = 85) developed MRONJ. The RR was 0.08 (95% CI 0.00 to 1.51). We rated the certainty of the evidence for the primary outcome to be very low due to imprecision and very serious risk of bias (high or unclear risk of selection bias, performance bias, detection bias, and attrition bias). See <a href="./full#CD012432-tbl-0002">summary of findings Table 2</a> and <a href="./references#CD012432-fig-0005" title="">Analysis 2.1</a>. </p> </section> <section id="CD012432-sec-0091"> <h6 class="title">Rate of complications and side effects of the intervention</h6> <p>No intraoperative complications were observed in either of the groups.</p> </section> </section> <section id="CD012432-sec-0092"> <h5 class="title">Delicate surgery and closure by primary intention (experimental) versus non‐traumatic tooth avulsion and closure by secondary intention (control) for the prophylaxis of MRONJ  </h5> <p>One RCT with 700 participants compared wound closure by primary intention with wound closure by secondary intention after dental extractions in individuals treated with oral bisphosphonates (<a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>). </p> <section id="CD012432-sec-0093"> <h6 class="title">Incidence of MRONJ</h6> <p>The participants were regularly monitored for clinical signs of MRONJ: pain, swelling, and non‐healing exposed necrotic bone or fistulas, or both, with connection to the bone. In both study arms, no case of postoperative MRONJ was observed. </p> </section> <section id="CD012432-sec-0094"> <h6 class="title">Rate of complications and side effects of the intervention</h6> <p>No intraoperative complications were observed in either of the two groups.</p> </section> </section> <section id="CD012432-sec-0095"> <h5 class="title">Primary closure of the extraction socket with a mucoperiosteal flap (experimental) versus application of platelet‐rich fibrin without primary closure (control) for the prophylaxis of MRONJ  </h5> <p>One RCT, which randomised 77 participants, reported on the effects of a PRF clot inserted into the extraction socket without primary closure versus primary closure of the extraction socket with a mucoperiosteal flap after tooth extraction (<a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>).  </p> <section id="CD012432-sec-0096"> <h6 class="title">Incidence of MRONJ</h6> <p>All participants had complete mucosal coverage without any signs of MRONJ at the final control examination 90 days postoperatively. </p> </section> <section id="CD012432-sec-0097"> <h6 class="title">Rate of complications and side effects of the intervention</h6> <p>No intraoperative complications occurred in either of the groups. Postoperative complications were found in six  participants (15.4%) in the mucoperiosteal flap group and in one participant (2.6%) in the PRF group. Postoperative complications were defined as any deviation from the normal postoperative course such as delayed wound healing, inflammation at the site of extraction, postoperative hematoma/haemorrhage, exposed bone/sequestrum.  </p> </section> </section> <section id="CD012432-sec-0098"> <h5 class="title">Subperiosteal prepared (SPP) mucoperiosteal flap versus epiperiosteal prepared (EPP) mucosa flap for the prevention of MRONJ in individuals treated with antiresorptive therapy for cancer or osteoporosis who underwent dental extractions </h5> <p>One RCT with 160 participants compared two methods of alveoplasty, namely the epiperiosteal prepared (EPP) mucosal flap and the subperiosteal prepared (SPP) mucoperiosteal flap after tooth extraction (<a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>).  </p> <section id="CD012432-sec-0099"> <h6 class="title">Incidence of MRONJ</h6> <p>Six months after surgery, no participant in the EPP group (N = 67) but 5 participants (7.7%) in the SPP group (N = 65) had MRONJ. Diagnosis of MRONJ was based on the absence of full mucosal integrity. The RR was 0.09 (95% CI 0.00 to 1.56). We rated the certainty of the evidence for the primary outcome to be low due to imprecision and serious risk of bias (unclear selection bias, detection bias, high risk of performance bias, attrition bias and reporting bias). See <a href="./full#CD012432-tbl-0003">summary of findings Table 3</a> and <a href="./references#CD012432-fig-0006" title="">Analysis 3.1</a>.  </p> </section> </section> </section> <section id="CD012432-sec-0100"> <h4 class="title">Treatment of MRONJ</h4> <section id="CD012432-sec-0101"> <h5 class="title">Hyperbaric oxygen as an adjunct to conventional therapy (experimental) versus conventional therapy (control) for treatment of MRONJ </h5> <p>One RCT with 49 participants analysed the healing of MRONJ using HBO treatment in addition to standard care (antiseptic rinses, antibiotics, surgery) (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>). All participants terminated bisphosphonate administration before or at the time of consent, except one who continued bisphosphonate administration for one month after the initial examination. </p> <section id="CD012432-sec-0102"> <h6 class="title">Healing of MRONJ</h6> <p>Oral lesions were graded by size and number, and staged by clinical severity. The last contact was intended to be 24 months after consent; however, only 18 participants completed the full 24‐month observation period. Healing was defined as gingival coverage with no exposed bone. HBO in addition to standard care did not improve healing from MRONJ at any of the investigated time points (at last follow‐up: RR 1.56; 95% CI 0.77 to 3.18; n = 46). We rated the certainty of the evidence for the primary outcome to be very low due to imprecision and very serious risk of bias (unclear and high risk of selection bias, performance bias, detection bias, and attrition bias; failure to adhere to the intention‐to‐treat principle). See <a href="./full#CD012432-tbl-0004">summary of findings Table 4</a> and <a href="./references#CD012432-fig-0007" title="">Analysis 4.1</a>. </p> </section> <section id="CD012432-sec-0103"> <h6 class="title">Quality of life</h6> <p>Quality of life (QoL) was measured using the Duke Health Profile, a 17‐question generic self‐reporting instrument with six health domains (physical, mental, social, general, perceived health, and self‐esteem) and four dysfunction measurements (anxiety, depression, pain, and disability) (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>). QoL assessments were recorded at the time of the initial interview and after six months. Only within‐group comparisons for each domain were provided based on a dichotomous classification (‘improved’, ‘no change, or worse’). Because no score values were provided, we were unable to make a between‐group analysis. </p> </section> </section> <section id="CD012432-sec-0104"> <h5 class="title">Autofluorescence‐guided bone surgery (experimental) versus tetracycline fluorescence‐guided bone surgery (control) in individuals with MRONJ referred for surgical treatment </h5> <p>One RCT with 40 participants compared autofluorescence‐guided and tetracycline fluorescence‐guided bone surgery for the treatment of MRONJ (<a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>). </p> <section id="CD012432-sec-0105"> <h6 class="title">Healing of MRONJ</h6> <p>The primary endpoint reported by <a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a> was success rate. Success was defined as the absence of a MRONJ site after surgery, specified as the maintenance of full mucosal coverage (mucosal integrity) after surgery at the time of the evaluation. All measurements were acquired at five specific time points: preoperatively, and 10 days, eight weeks, six months, and one year after surgery. There was no relevant difference between the autofluorescence‐ and the tetracycline fluorescence‐guided groups at any of the time points (at one‐year follow‐up: RR 1.05; 95% CI 0.86 to 1.30; n = 34). We rated the certainty of the evidence for the primary outcome to be very low due to imprecision and very serious risk of bias (unclear and high risk of selection bias, performance bias, and detection bias). See <a href="./full#CD012432-tbl-0005">summary of findings Table 5</a> and <a href="./references#CD012432-fig-0008" title="">Analysis 5.1</a>. </p> </section> </section> <section id="CD012432-sec-0106"> <h5 class="title">Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) versus platelet‐rich fibrin alone (control) for treatment of MRONJ </h5> <p>One RCT compared the healing results of the combined use of bone morphogenetic protein‐2 (BMP‐2) and platelet‐rich fibrin (PRF) with the use of PRF alone in patients with MRONJ and bony lesions requiring surgical debridement (<a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a>). Fifty‐five patients were included, of whom 30 patients were assigned to the experimental group (PRF and rhBMP‐2) and 25 participants to the PRF control group.  </p> <section id="CD012432-sec-0107"> <h6 class="title">Healing of MRONJ</h6> <p>Healing of MRONJ was defined as full mucosal coverage without clinical or radiographical evidence of MRONJ. At 16 weeks postoperatively, 29 participants (96.7%) of the PRF plus BMP group and 22 participants (88.0%) of the PRF group showed complete resolution (RR 1.10, 95% CI 0.94 to 1.29). We rated the certainty of the evidence for the primary outcome to be very low due to very serious limitations of imprecision and very serious risk of bias (unclear risk of selection bias, detection bias, high risk of performance bias, attrition bias, reporting bias). See <a href="./full#CD012432-tbl-0006">summary of findings Table 6</a> and <a href="./references#CD012432-fig-0009" title="">Analysis 6.1</a>.  </p> </section> </section> <section id="CD012432-sec-0108"> <h5 class="title">Autofluorescence‐guided bone surgery (experimental) versus conventional bone surgery (control) for treatment of MRONJ </h5> <p>An RCT with 36 participants investigated whether autofluorescence‐guided delineation of resection margins for necrotic bone results in improved MRNOJ cure rates compared with conventional bone surgery based on surgeon experience alone (<a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>). </p> <section id="CD012432-sec-0109"> <h6 class="title">Healing of MRONJ</h6> <p>Healing of MRONJ was defined as the absence of exposed necrotic bone with full mucosal coverage and no signs of residual infection (pain, purulent discharge, or numbness) at one week, one month, six months, and one year after surgery. The primary outcome as reported by <a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a> was mucosal integrity six months after surgery. MRONJ cure rates were not different between both treatment arms at one‐year follow‐up (RR 1.08; 95% CI 0.85 to 1.37; n = 30) or any other time points. We rated the certainty of the evidence for the primary outcome to be very low due to very serious imprecision and serious risk of bias (high selection bias, performance bias, attrition bias, unclear risk of detection bias). See <a href="./full#CD012432-tbl-0007">summary of findings Table 7</a> and <a href="./references#CD012432-fig-0010" title="">Analysis 7.1</a>. </p> </section> </section> <section id="CD012432-sec-0110"> <h5 class="title">Platelet‐rich fibrin after bone surgery (experimental) versus surgery alone (control) for treatment of MRONJ </h5> <p><a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a> recruited 47 participants with the diagnosis of stage II or III of MRONJ to compare the efficacy of bone surgery either with or without  PRF for mucosal healing in an RCT.  </p> <section id="CD012432-sec-0111"> <h6 class="title">Healing of MRONJ</h6> <p><a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a> reported mucosal integrity, absence of residual infection or cutaneous fistulas, and no re‐intervention necessary to healing as study outcomes, evaluated at one month, six months, and one year after surgery. We used a composite endpoint requiring mucosal integrity and  absence of residual infection or cutaneous fistulas to define successful healing of MRONJ at 1‐year follow‐up. The RR was 1.05 (95% CI 0.90 to 1.22). We rated the certainty of the evidence for the primary outcome to be very low due to very serious limitation of imprecision and serious risk of bias (unclear selection bias, detection bias, high risk of performance bias, reporting bias).  See <a href="./full#CD012432-tbl-0008">summary of findings Table 8</a> and <a href="./references#CD012432-fig-0011" title="">Analysis 8.1</a>. </p> <p>The need for re‐intervention may be considered a treatment failure, i.e. the endpoint of cure would likely not have been achieved without re‐intervention. Therefore, as part of a sensitivity analysis, we additionally considered the combined endpoint of mucosal integrity, absence of residual infection or cutaneous fistulas, and no re‐intervention necessary. The RR was 1.60 (95% CI 1.04 to 2.46). We rated the certainty of the evidence for the primary outcome to be very low due to very serious limitation of imprecision and serious risk of bias (unclear selection bias, detection bias, high risk of performance bias, reporting bias). See <a href="./full#CD012432-tbl-0008">summary of findings Table 8</a> and <a href="./references#CD012432-fig-0012" title="">Analysis 8.2</a>. </p> </section> </section> <section id="CD012432-sec-0112"> <h5 class="title">Concentrated growth factor and primary wound closure (experimental) versus primary wound closure only (control) for treatment of MRONJ </h5> <p>One RCT examined the effect of concentrated growth factor (CGF) applied to the surgical site compared with a control group without CGF (<a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>). Twenty‐eight patients with stage 2 or 3 MRONJ and inadequate improvement with conservative treatment who underwent surgical debridement were randomised 1:1.   </p> <section id="CD012432-sec-0113"> <h6 class="title">Healing of MRONJ </h6> <p>Healing was defined as soft tissue coverage without signs of infection or necrotic bone exposure. Healing of MRONJ was observed in 11 participants (78.6%) in the CGF group and 8 participants (57.1%) in the control group at six months after surgery (RR 1.38, 95% CI 0.81 to 2.34). We rated the certainty of the evidence for the primary outcome to be very low due to serious risk of bias (unclear selection bias, high risk of performance bias), very serious limitation of indirectness (only female participants with osteoporosis) and very serious limitation of imprecision (few participants). See <a href="./full#CD012432-tbl-0009">summary of findings Table 9</a> and <a href="./references#CD012432-fig-0013" title="">Analysis 9.1</a>.   </p> </section> </section> <section id="CD012432-sec-0114"> <h5 class="title">Teriparatide 20 μg daily (experimental) versus placebo (control), in addition to standard care, for treatment of MRONJ </h5> <p>One RCT evaluated the efficacy of eight weeks of subcutaneous teriparatide (20 mg/day) versus placebo injections in addition to calcium and vitamin D supplementation and standard clinical care in 34 participants with established MRONJ (<a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>). Participants were observed for 12 months, with primary outcomes that included the clinical and radiologic resolution of MRONJ lesions. </p> <section id="CD012432-sec-0115"> <h6 class="title">Healing of MRONJ</h6> <p>The proportion of participants without any unresolved lesion at 52 weeks was 27.8% in the placebo group versus 26.7% in the teriparatide group (RR 0.96, 95% CI 0.31 to 2.95). We rated the certainty of the evidence for the primary outcome to be low due to imprecision and serious risk of bias (unclear selection bias, high risk of attrition bias and reporting bias). We downgraded the certainty of the evidence by two levels due to imprecision and serious risk of bias (unclear selection bias, high risk of attrition bias and reporting bias). See <a href="./full#CD012432-tbl-0010">summary of findings Table 10</a> and <a href="./references#CD012432-fig-0014" title="">Analysis 10.1</a>. </p> </section> </section> <section id="CD012432-sec-0116"> <h5 class="title">Teriparatide 56.5 μg weekly (experimental) versus teriparatide 20 μg daily (control) in addition to conventional treatment of MRONJ </h5> <p><a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a> examined the clinical outcomes of teriparatide (TPTD) treatment in 13 patients with stage II‐III bisphosphonate‐induced ONJ and compared two TPTD dosing regimens, namely 20 μg TPTD injections daily for six months versus 1×/week 56.5 μg TPTD injections for six months, in an RCT. After one dropout, 12 participants, six in each group, were analysed. The last follow‐up time point was six months after the start of teriparatide treatment.  </p> <section id="CD012432-sec-0117"> <h6 class="title">Healing of MRONJ</h6> <p>The authors reported MRONJ remission as an outcome measure based on the clinical staging of MRONJ. However, the report aggregated the rates of partial remission and complete remission, leaving the cure rate, i.e. the rate of complete remission, unclear. At the end of six months of TPTD treatment, partial remission or complete remission was achieved in three of six participants in the experimental group and in five of six participants in the control group (RR 0.60, 95% CI 0.25 to 1.44). We rated the certainty of the evidence for the primary outcome to be very low due to imprecision and very serious risk of bias (unclear selection bias and detection bias, high risk of performance bias, attrition bias and reporting bias). See <a href="./full#CD012432-tbl-0011">summary of findings Table 11</a> and <a href="./references#CD012432-fig-0015" title="">Analysis 11.1</a>. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012432-sec-0118" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012432-sec-0118"></div> <p>At present, the mechanisms of medication‐related osteonecrosis of the jaw (MRONJ) are not well known, and the prevention and treatment of MRONJ remains challenging. Thus, it is important to identify effective strategies for managing this well‐known complication of antiresorptive medication. </p> <section id="CD012432-sec-0119"> <h3 class="title" id="CD012432-sec-0119">Summary of main results</h3> <p>For the prevention of MRONJ, we identified five randomised controlled trials (RCTs), each evaluating different interventions (<a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>; <a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>; <a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>).  </p> <p>There is very low‐certainty evidence that dental examinations at three‐month intervals and preventive treatments are more effective than standard care in reducing the incidence proportion and the incidence rate of MRONJ in men taking intravenous bisphosphonates for advanced cancer and bone metastases.  </p> <p>Tooth extractions are considered one of the main triggers for the development of MRONJ and various preventive measures have been tested (<a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>; <a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>). After evaluating the available evidence, it is not possible to assert or refute a benefit of any of the interventions reviewed, such as plasma rich in growth factors (PRGF) or platelet‐rich fibrin (PRF) inserted into the postextraction alveolus or a specific surgical strategy (i.e. wound closure by primary or secondary intention) or a specific alveoplasty technique (i.e. epiperiosteal  or subperiosteal wound closure) for prevention of MRONJ.  </p> <p>We identified eight RCTs that evaluated specific methods to improve the healing of MRONJ, namely hyperbaric oxygen (HBO) therapy (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>), fluorescence‐guided bone surgery (<a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>; <a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>), growth factors such as  PRF, concentrated growth factor or bone morphogenic protein 2 (<a href="./references#CD012432-bbs2-0003" title="GiudiceA , BaroneS , BennardoF , FortunatoL . Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2018;126(5):390-403. [DOI: 10.1016/j.oooo.2018.06.007] [PMID: 29175416]">Giudice 2018b</a>; <a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>; <a href="./references#CD012432-bbs2-0008" title="Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?Journal of Oral and Maxillofacial Surgery2017;75(6):1176-84. [DOI: 10.1016/j.joms.2016.12.005] [PMID: 28042979]">Park 2017</a>), and teriparatide (<a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>). There was insufficient evidence to either claim or refute a benefit of any of these therapies for improved healing of MRONJ. There was also insufficient evidence to support either autofluorescence‐guided bone surgery or tetracycline fluorescence‐guided bone surgery for improved healing of MRONJ. The small sample size may have contributed to a lack of measurable effect.  </p> </section> <section id="CD012432-sec-0120"> <h3 class="title" id="CD012432-sec-0120">Overall completeness and applicability of evidence</h3> <p>The types of interventions evaluated in the included RCTs varied widely and so we were not able to combine data from different studies. </p> <p>Most RCTs included only people with bisphosphonates for the treatment of cancer or osteoporosis, or both. Two studies included patients treated with both denosumab and bisphosphonates (<a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>). Although another study also allowed individuals treated with denosumab to participate, only individuals treated with bisphosphonates were included (<a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>). None of the trials investigated the association between MRONJ and antiangiogenic medications. Thus, the included RCTs do not cover the entire spectrum of medications associated with MRONJ. </p> <p>One trial recruited a highly selective group of participants (i.e. men with prostate cancer receiving zoledronic acid for the treatment of bone metastases) (<a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>). The applicability of the results of this study to other populations is unclear. </p> <p>A subgroup of individuals, namely those with a history of head and neck radiation therapy, were generally excluded from the RCTs due to the widely accepted case definition of MRONJ. Although exclusion of these individuals may be useful in reducing the heterogeneity of the study populations and in controlling for an important influencing variable, this may have impaired the overall completeness of evidence. </p> </section> <section id="CD012432-sec-0121"> <h3 class="title" id="CD012432-sec-0121">Quality of the evidence</h3> <p>We judged the overall certainty of the evidence to be low or very low, meaning that we are uncertain about the estimates of effect. </p> <p>All included studies were assessed to have a high risk of bias overall, as they had at least one domain rated at high risk. All trials but one (<a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>) were open‐label. Due to their nature, some interventions could not be blinded to participants or surgeons. In only a few studies were outcome assessors blinded (<a href="./references#CD012432-bbs2-0011" title="DRKS00010106. Comparison of two different mucosal closure techniques after tooth extraction in high risk patients with antiresortive medication intake - a prospective, randomized, blinded feasebility [sic] study. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010106 (first received 31 August 2020). RistowO , RückschloßT , MoratinJ , MüllerM , KühleR , DominikH , et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Diseases2020;27(3):532-46. [DOI: 10.1111/odi.13556] [PMID: 32875698]">Ristow 2020</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>; <a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>). Altogether, a lack of blinding confers a high risk of bias. In one trial, the length of follow‐up differed between comparison groups, which may have biased the results of the study (<a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>). A high and unbalanced rate of cross‐overs after randomisation between the comparison groups in two trials may also have conferred a high risk of bias (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>; <a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a>). We also downgraded the certainty of the evidence due to imprecision. This is because most studies included relatively few participants (<a href="./references#CD012432-bbs2-0001" title="FreibergerJJ , Padilla-BurgosR , McGrawT , SulimanHB , KraftKH , StolpBW , et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery2012;70(7):1573-83. [DOI: 10.1016/j.joms.2012.04.001] [PMID: 22698292]NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007). ">Freiberger 2012</a>; <a href="./references#CD012432-bbs2-0010" title="RistowO , OttoS , GeißC , KehlV , BergerM , TroeltzschM , et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery2017;46(2):157-66. [DOI: 10.1016/j.ijom.2016.10.008] [PMID: 27856150]">Ristow 2016</a>; <a href="./references#CD012432-bbs2-0002" title="GiudiceA ,  Bennardo F,  Barone S,  Antonelli A,  Figliuzzi MM,  Fortunato L. Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. Journal of Oral Maxillofacial Surgery2018;76(5):982-95. [DOI: 10.1016/j.joms.2017.10.024] [PMID: 30108028]">Giudice 2018a</a>; <a href="./references#CD012432-bbs2-0007" title="OhbayashiY , IwasakiA , NakaiF , MashibaT , MiyakeM . A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporosis International2020;31(3):577-85. [DOI: 10.1007/s00198-019-05199-w] [PMID: 31768589]">Ohbayashi 2020</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>; <a href="./references#CD012432-bbs2-0012" title="ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw?trialsearch.who.int/?TrialID=ACTRN12612000950864 (first received 5 September 2012). SimIW , BorromeoGL , TsaoC , HardimanR , HofmanMS , Papatziamos HjelleC , et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. Journal of Clinical Oncology2020;38(26):2971-80. [DOI: 10.1200/JCO.19.02192] [PMID: 32614699]">Sim 2020</a>; <a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>) or had few or no events  (<a href="./references#CD012432-bbs2-0004" title="MozzatiM , ArataV , GallesioG , CarossaS . A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint, Bone, Spine2011;786(6):648-9. [DOI: 10.1016/j.jbspin.2011.04.017] [PMID: 21703903]MozzatiM , ArataV , GallesioG . Tooth extraction in patients on zoledronic acid therapy. Oral Oncology2012;48(9):817-21. [DOI: 10.1016/j.oraloncology.2012.03.009] [PMID: 22483860]">Mozzati 2012</a>; <a href="./references#CD012432-bbs2-0005" title="MozzatiM , ArataV , GallesioG , CarossaS . Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine2011;78(6):647-8. [DOI: 10.1016/j.jbspin.2011.04.018] [PMID: 21703902]MozzatiM , ArataV , GallesioG . Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International2013;24(5):1707-1. [DOI: 10.1007/s00198-012-2239-8] [PMID: 23288026]">Mozzati 2013</a>; <a href="./references#CD012432-bbs2-0009" title="PoxleitnerP , SteybeD , Kroneberg P ErmerMA , Yalcin-ÜlkerGM , SchmelzeisenR , et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery2020;48(4):444-51. [DOI: 10.1016/j.jcms.2020.02.006] [PMID: 32122726]">Poxleitner 2020</a>), making it impossible to determine the effect estimates, or the effect estimates had wide 95% confidence intervals. In two comparisons, the certainty of evidence was downgraded due to indirectness (based on <a href="./references#CD012432-bbs2-0006" title="MückeT , DeppeH , HeinJ , WolffKD , MitchellDA , KestingMR , et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. Journal of Cranio-maxillo-facial Surgery2016;44(10):1689-93. [DOI: 10.1016/j.jcms.2016.07.026] [27555374]">Mücke 2016</a> and <a href="./references#CD012432-bbs2-0013" title="NCT04531800. Surgical management of medication related osteonecrosis of the jaws with concentrated growth factor. clinicaltrials.gov/ct2/show/NCT04531800 (first received 31 August 2020). YüceMO , AdaliE , IsikG . The effect of concentrated growth factor (CGF) in the surgical treatment od medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clinical Oral Investigations2021;25(7):4529-41. [DOI: 10.1007/s00784-020-03766-8] [PMID: 33392802]">Yüce 2021</a>); only one sex (either males or females) was included with one particular disease or the participants were high‐risk patients. </p> </section> <section id="CD012432-sec-0122"> <h3 class="title" id="CD012432-sec-0122">Potential biases in the review process</h3> <p>The methods we used in the review were established and documented in advance of the review being undertaken. We were not influenced by prior knowledge of the study results when making judgements regarding study eligibility. We made no subsequent changes to the types of studies and types of participants to be included in the review as specified in the protocol, with one exception. For trials investigating the effects of interventions for the prophylaxis of MRONJ, we originally required a follow‐up period of at least three years. The three‐year follow‐up threshold, however, turned out not to be a feasible selection criterion (see <a href="#CD012432-sec-0033">Primary outcomes</a>). We consider this change to the inclusion criteria to be well justified, however, and we do not believe that we have introduced a relevant selection bias. </p> <p>Cochrane Oral Health Information Specialist (Anne Littlewood) conducted comprehensive searches of journal and conference databases to ensure that all published and unpublished trials were identified. We did not limit the searches to a particular language. Two review authors independently extracted the trials that met the inclusion criteria. The study authors were contacted where necessary to ascertain if any newer data were available following publication. </p> </section> <section id="CD012432-sec-0123"> <h3 class="title" id="CD012432-sec-0123">Agreements and disagreements with other studies or reviews</h3> <p>In the last two years, several systematic reviews have been published addressing the prophylaxis and treatment of MRONJ (<a href="./references#CD012432-bbs2-0053" title="CabrasM , GambinoA , BroccolettiR , SciasciaS , ArduinoPG . Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics. Journal of Oral Science2021;63(3):217-26.">Cabras 2021</a>; <a href="./references#CD012432-bbs2-0062" title="Di FedeO , CanepaF , PanzarellaV , MauceriR , Del GaizoC , BedogniA , et al. The treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): a systematic review with a pooled analysis of only surgery versus combined protocols. International Journal of Environmental Research and Public Health2021;18(16):8432-54.">Di Fede 2021</a>; <a href="./references#CD012432-bbs2-0065" title="Dos SantosFL , AbreuLG , CalderipeCB , MartinsMD , SchuchLF , VasconcelosAC . Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.. Osteoporosis International2021;32(8):1-11.">Dos Santos Ferreira 2021</a>; <a href="./references#CD012432-bbs2-0069" title="FortunatoL , BennardoF , BuffoneC , GiudiceA . Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review. Journal of Cranio-maxillo-facial Surgery2020;48(3):268-85.">Fortunato 2020</a>; <a href="./references#CD012432-bbs2-0072" title="GokerF , GrecchiE , GrecchiF , FrancettiL , Del FabbroM . Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review. European Review for Medical and Pharmacological Sciences2021;25(6):2662-73.">Goker 2021</a>; <a href="./references#CD012432-bbs2-0073" title="GovaertsD , PiccartF , OckermanA , CoropciucR , PolitisC , JacobsR . Adjuvant therapies for MRONJ: a systematic review.. Bone2020;141:115676.">Govaerts 2020</a>; <a href="./references#CD012432-bbs2-0061" title="deSouza TolentinoE , deCastroTF , MichellonFC , PassoniAC , OrtegaLJA , Iwaki LilianCV , et al. Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review.. Head Neck2019;41(12):4209-28.">de Souza Tolentino 2019</a>). Unlike our work, which included only RCTs, these reviews additionally included non‐RCTs, such as case reports, case series, retrospective studies, and prospective cohort studies. The reviews investigated the efficacy of hyperbaric oxygen, low‐intensity laser, autologous platelet concentrates (platelet‐rich plasma, plasma‐rich growth factors, and platelet‐rich fibrin), teriparatide, ozone applications, or fluorescence‐guided surgery in the treatment of MRONJ (<a href="./references#CD012432-bbs2-0061" title="deSouza TolentinoE , deCastroTF , MichellonFC , PassoniAC , OrtegaLJA , Iwaki LilianCV , et al. Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review.. Head Neck2019;41(12):4209-28.">de Souza Tolentino 2019</a>; <a href="./references#CD012432-bbs2-0062" title="Di FedeO , CanepaF , PanzarellaV , MauceriR , Del GaizoC , BedogniA , et al. The treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): a systematic review with a pooled analysis of only surgery versus combined protocols. International Journal of Environmental Research and Public Health2021;18(16):8432-54.">Di Fede 2021</a>; <a href="./references#CD012432-bbs2-0065" title="Dos SantosFL , AbreuLG , CalderipeCB , MartinsMD , SchuchLF , VasconcelosAC . Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.. Osteoporosis International2021;32(8):1-11.">Dos Santos Ferreira 2021</a>;  <a href="./references#CD012432-bbs2-0069" title="FortunatoL , BennardoF , BuffoneC , GiudiceA . Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review. Journal of Cranio-maxillo-facial Surgery2020;48(3):268-85.">Fortunato 2020</a>; <a href="./references#CD012432-bbs2-0072" title="GokerF , GrecchiE , GrecchiF , FrancettiL , Del FabbroM . Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review. European Review for Medical and Pharmacological Sciences2021;25(6):2662-73.">Goker 2021</a>; <a href="./references#CD012432-bbs2-0073" title="GovaertsD , PiccartF , OckermanA , CoropciucR , PolitisC , JacobsR . Adjuvant therapies for MRONJ: a systematic review.. Bone2020;141:115676.">Govaerts 2020</a>; <a href="./references#CD012432-bbs2-0061" title="deSouza TolentinoE , deCastroTF , MichellonFC , PassoniAC , OrtegaLJA , Iwaki LilianCV , et al. Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review.. Head Neck2019;41(12):4209-28.">de Souza Tolentino 2019</a>). Another focus of the reviews was prophylaxis of MRONJ by periprocedural administration of systemic antibiotics (<a href="./references#CD012432-bbs2-0053" title="CabrasM , GambinoA , BroccolettiR , SciasciaS , ArduinoPG . Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics. Journal of Oral Science2021;63(3):217-26.">Cabras 2021</a>) or autologous platelet concentrates (<a href="./references#CD012432-bbs2-0069" title="FortunatoL , BennardoF , BuffoneC , GiudiceA . Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review. Journal of Cranio-maxillo-facial Surgery2020;48(3):268-85.">Fortunato 2020</a>) in patients under antiresorptive and/or biologic agents undergoing tooth extraction or implant surgery. All these reviews agree that high‐quality research, i.e. randomised controlled trials with large samples are required before conclusive statements can be made regarding strategies for the prevention or treatment of MRONJ. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012432-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012432-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012432-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dental examinations at three‐month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ, Outcome 1: MRONJ (incidence proportion)" data-id="CD012432-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Dental examinations at three‐month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ, Outcome 1: MRONJ (incidence proportion) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dental examinations at three‐month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ, Outcome 2: MRONJ (incidence rate: MRONJ cases per patient‐year)" data-id="CD012432-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Dental examinations at three‐month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ, Outcome 2: MRONJ (incidence rate: MRONJ cases per patient‐year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Plasma rich in growth factors inserted into the postextraction alveolus in addition to standardised medical and surgical care (experimental) versus standardised medical and surgical care alone (control) for prophylaxis of MRONJ, Outcome 1: MRONJ (incidence proportion)" data-id="CD012432-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Plasma rich in growth factors inserted into the postextraction alveolus in addition to standardised medical and surgical care (experimental) versus standardised medical and surgical care alone (control) for prophylaxis of MRONJ, Outcome 1: MRONJ (incidence proportion) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment, Outcome 1: MRONJ after tooth extraction (assessed with: absence of complete mucosal integrity) at 6 months" data-id="CD012432-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment, Outcome 1: MRONJ after tooth extraction (assessed with: absence of complete mucosal integrity) at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Hyperbaric oxygen as an adjunct to conventional therapy (experimental) versus conventional therapy (control) for treatment of MRONJ, Outcome 1: Healing of MRONJ at last contact" data-id="CD012432-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Hyperbaric oxygen as an adjunct to conventional therapy (experimental) versus conventional therapy (control) for treatment of MRONJ, Outcome 1: Healing of MRONJ at last contact </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Autofluorescence‐guided bone surgery (experimental) versus tetracycline fluorescence‐guided bone surgery (control) for treatment of MRONJ, Outcome 1: Healing of MRONJ (defined as mucosal integrity) at 1 year" data-id="CD012432-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Autofluorescence‐guided bone surgery (experimental) versus tetracycline fluorescence‐guided bone surgery (control) for treatment of MRONJ, Outcome 1: Healing of MRONJ (defined as mucosal integrity) at 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) compared to platelet‐rich fibrin alone (control) for treatment of MRONJ., Outcome 1: Healing of MRONJ (defined as full mucosal coverage without clinical or radiographical evidence of MRONJ) after 16 weeks" data-id="CD012432-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) compared to platelet‐rich fibrin alone (control) for treatment of MRONJ., Outcome 1: Healing of MRONJ (defined as full mucosal coverage without clinical or radiographical evidence of MRONJ) after 16 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Autofluorescence‐guided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ, Outcome 1: Healing of MRONJ (defined as full mucosal coverage and no signs of residual infection) at 1 year" data-id="CD012432-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Autofluorescence‐guided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ, Outcome 1: Healing of MRONJ (defined as full mucosal coverage and no signs of residual infection) at 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ, Outcome 1: Healing of MRONJ (defined as absence of infection and mucosal integrity without fistula) at 1 year" data-id="CD012432-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ, Outcome 1: Healing of MRONJ (defined as absence of infection and mucosal integrity without fistula) at 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ, Outcome 2: Healing of MRONJ (defined as absence of infection, mucosal integrity without fistula,  and no need for re‐intervention) at 1 year" data-id="CD012432-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ, Outcome 2: Healing of MRONJ (defined as absence of infection, mucosal integrity without fistula,  and no need for re‐intervention) at 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Concentrated growth factor and primary wound closure (experimental) versus primary wound closure only (control) for treatment of MRONJ, Outcome 1: Healing of MRONJ (assessed with: mucosal integrity) at 6 months" data-id="CD012432-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Concentrated growth factor and primary wound closure (experimental) versus primary wound closure only (control) for treatment of MRONJ, Outcome 1: Healing of MRONJ (assessed with: mucosal integrity) at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Teriparatide 20 μg daily (experimental) versus placebo (control), in addition to standard care, for treatment of MRONJ, Outcome 1: Healing of MRONJ (defined as absence of any unresolved lesion) at 1 year" data-id="CD012432-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Teriparatide 20 μg daily (experimental) versus placebo (control), in addition to standard care, for treatment of MRONJ, Outcome 1: Healing of MRONJ (defined as absence of any unresolved lesion) at 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012432-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/urn:x-wiley:14651858:media:CD012432:CD012432-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Teriparatide 56.5 μg weekly (experimental) versus teriparatide 20 μg daily (control), in addition to standard care, for treatment of MRONJ, Outcome 1: Healing of MRONJ (defined as partial or complete remission) at 6 months" data-id="CD012432-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_t/tCD012432-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Teriparatide 56.5 μg weekly (experimental) versus teriparatide 20 μg daily (control), in addition to standard care, for treatment of MRONJ, Outcome 1: Healing of MRONJ (defined as partial or complete remission) at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/media/CDSR/CD012432/image_n/nCD012432-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dental examinations at three‐month intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dental examinations at three‐month intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people at risk of MRONJ<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> dental examinations at three‐month intervals and preventive treatments (experimental)<br/><b>Comparison:</b> standard care (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard care (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dental examinations at 3‐month intervals and preventive treatments (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRONJ (incidence proportion)</b><br/>Diagnostic criteria for MRONJ: non‐healing exposed bone in mandible or maxilla for longer than 8 weeks without any change of the stage of disease </p> <p> </p> <p>Follow‐up: mean 32 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/>(5 to 91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.10</b><br/>(0.02 to 0.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants: high‐risk (i.e. individuals with cancer exposed to intravenous zoledronic acid). </p> <p>The outcome MRONJ was also reported as number of cases per patient‐year (incidence rate): rate ratio 0.18 (95% CI 0.04 to 0.74). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to very serious risk of bias (high and unbalanced rate of crossovers after randomisation; high dropout rates due to high mortality; failure to adhere to the intention‐to‐treat principle; mean follow‐up differed between experimental and control groups) and very serious limitation of indirectness (all male and high‐risk patients). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dental examinations at three‐month intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to a standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people treated with IV bisphosphonates who need dental extractions<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> dental extraction protocol with PRGF (experimental)<br/><b>Comparison:</b> standard dental extraction protocol without PRGF (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard dental extraction protocol without PRGF (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dental extraction protocol with PRGF (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRONJ (incidence proportion)</b><br/>Diagnostic criteria of MRONJ: pain, swelling, and non‐healing exposed necrotic bone or fistulae, or both, with connection to the bone<br/>  </p> <p>Follow‐up: 24‐60 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b><br/>(0 to 89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.08</b><br/>(0.00 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants: high risk, i.e. individuals with cancer exposed to IV zoledronic acid</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>IV:</b> intravenous: <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of evidence by three levels due to imprecision and very serious risk of bias (high or unclear risk of selection bias, performance bias, detection bias, and attrition bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people on antiresorptive treatment<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> subperiosteal wound closure<br/><b>Comparison:</b> epiperiosteal wound closure after tooth extraction </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with epiperiosteal wound closure after tooth extraction</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with subperiosteal wound closure after tooth extraction</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRONJ after tooth extraction</b> Assessed with: absence of complete mucosal integrity </p> <p> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b><br/>(0 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.09</b><br/>(0.00 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 patients changed intervention from epiperiosteal wound closure to subperiosteal wound closure. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by two levels due to imprecision and serious risk of bias (unclear selection bias, detection bias, high risk of performance bias, attrition bias and reporting bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hyperbaric oxygen therapy (HBO) as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HBO as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people with MRONJ<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> HBO as an adjunct to conventional therapy (experimental)<br/><b>Comparison:</b> conventional therapy (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with conventional therapy (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with HBO therapy as an adjunct to conventional therapy (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ</b><br/>Diagnostic criteria for healing of MRONJ: gingival coverage with no exposed bone </p> <p> </p> <p>Follow‐up: up to 24 months (outcome was measured at last follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>520 per 1000</b><br/>(257 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.56</b><br/>(0.77 to 3.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HBO:</b> hyperbaric oxygen therapy; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to imprecision and very serious risk of bias (unclear and high risk of selection bias, performance bias, detection bias, and attrition bias; failure to adhere to the intention‐to‐treat principle). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hyperbaric oxygen therapy (HBO) as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Autofluorescence‐guided bone surgery (experimental) compared to tetracycline fluorescence‐guided bone surgery (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Autofluorescence‐guided bone surgery (experimental) compared to tetracycline fluorescence‐guided bone surgery (control) for treatment of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people with MRONJ<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> autofluorescence‐guided bone surgery (experimental)<br/><b>Comparison:</b> tetracycline fluorescence‐guided bone surgery (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with tetracycline fluorescence‐guided bone surgery (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with autofluorescence‐guided bone surgery (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ</b><br/>Criteria for healing of MRONJ: mucosal integrity </p> <p> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>889 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>933 per 1000</b><br/>(764 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/>(0.86 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 <br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to imprecision and very serious risk of bias (unclear and high risk of selection bias, performance bias, and detection bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Autofluorescence‐guided bone surgery (experimental) compared to tetracycline fluorescence‐guided bone surgery (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) compared to platelet‐rich fibrin alone (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) compared to platelet‐rich fibrin alone (control) for treatment of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) </p> <p><b>Comparison:</b> platelet‐rich fibrin only (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with platelet‐rich fibrin only (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with bone morphogenetic protein‐2 adjacent to platelet‐rich fibrin (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ </b> </p> <p>Defined in the study as full coverage with absence of exposed bone, mucosal swelling and erythema, purulent drainage, intra‐ and extra oral fistula and/or any pain or discomfort </p> <p> </p> <p>Follow‐up: 16 weeks post surgery</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>880 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>968 per 1000</b><br/>(831 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b> (0.94 to 1.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 <br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to very serious limitations of imprecision and very serious risk of bias (unclear risk of selection bias, detection bias, high risk of performance bias, attrition bias, reporting bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) compared to platelet‐rich fibrin alone (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Autofluorescence‐guided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Autofluorescence‐guided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> autofluorescence guided surgery (experimental) </p> <p><b>Comparison:</b> conventional surgery (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with conventional surgery (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with autofluorescence guided surgery (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ </b> </p> <p>Criteria for healing: absence of bone exposure</p> <p> </p> <p>Follow‐up: 1 year (at last follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>867 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>933 per 1000</b><br/>(734 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> (0.85 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High drop‐out rate. 6 patients were excluded due to mortality and no show at follow‐up appointments. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty  of the evidence by three levels due to very serious imprecision and serious risk of bias (high selection bias, performance bias, attrition bias, unclear risk of detection bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Autofluorescence‐guided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> platelet‐rich fibrin (experimental) </p> <p><b>Comparison:</b> conventional (control) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgery alone (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with platelet‐rich fibrin after bone surgery (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ</b> Defined as absence of infection and mucosal integrity without fistula </p> <p> </p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>913 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>958 per 1000</b><br/>(824 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> (0.90 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome healing of MRONJ was also reported as absence of infection, mucosal integrity without fistula, no need for re‐intervention: rate ratio 1.60 (95% CI 1.04 to 2.46). Follow‐up: 1 year </p> <p>See <a href="./references#CD012432-fig-0012" title="">Analysis 8.2</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to very serious limitation of imprecision and serious risk of bias (unclear selection bias, detection bias, high risk of performance bias, reporting bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Concentrated growth factor and primary wound closure (experimental) versus primary wound closure only (control) for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Concentrated growth factor and primary wound closure compared with primary wound closure only for treatment of MRONJ </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people with MRONJ<br/><b>Setting: </b> surgical treatment<br/><b>Intervention:</b> concentrated growth factor and primary wound closure<br/><b>Comparison:</b> primary wound closure only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with primary wound closure only (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with concentrated growth factor and primary wound closure (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ</b> Defined as soft tissue healing<br/>Assessed with: mucosal integrity (without flap dehiscence or infection) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>521 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b><br/>(89 to 922) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.38</b><br/>(0.81 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels because of serious risk of bias (unclear selection bias, high risk of performance bias), very serious limitation of indirectness (only female participants with osteoporosis) and very serious limitation of imprecision (few participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Concentrated growth factor and primary wound closure (experimental) versus primary wound closure only (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Teriparatide 20 μg daily (experimental) versus placebo (control) in addition to standard care for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Teriparatide 20 μg daily compared with placebo for treatment of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> people  with MRONJ </p> <p><b>Settings:</b> outpatient and inpatient treatment </p> <p><b>Intervention:</b> teriparatide 20 μg daily </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with teriparatide 20 µg daily (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Healing of MRONJ</b> </p> <p>Primary outcomes were the clinical and radiologic resolution of MRONJ lesions, as evaluated by oral examination and CBCT imaging; secondary outcomes included improvement in MRONJ stage, change in MRONJ lesion size, quality of life, bone mineral density, and evidence of osteoblastic response measured biochemically using P1NP and radiologically using 18F‐fluoride PET‐CT imaging </p> <p> </p> <p>Last follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> <p>(87 to 819)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96  </b>(0.31 to 2.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 33</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by two levels due to imprecision and serious risk of bias (unclear selection bias, high risk of attrition bias and reporting bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Teriparatide 20 μg daily (experimental) versus placebo (control) in addition to standard care for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012432-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Teriparatide 56.5 μg weekly (experimental) versus teriparatide 20 μg daily (control) in addition to standard care for treatment of MRONJ</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Teriparatide 56.5 μg weekly (experimental) compared with teriparatide 20 μg daily (control) in addition to standard care for treatment of MRONJ</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> outpatient and inpatient treatment </p> <p><b>Intervention:</b> teriparatide 56.5 μg weekly in addition to standard care </p> <p><b>Comparison:</b> teriparatide 20 μg daily in addition to standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with teriparatide 20 μg daily (control)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with teriparatide 56.5 µg weekly (experimental)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Healing of MRONJ</b> </p> <p>Measured changes in MRONJ clinical stage at 6 months after the start of the treatment as clinical course, changes in bone metabolism (using bone scintigraphy), percentage of bone formation on the osteolysis of MRONJ, and measurement of bone turnover markers) </p> <p> </p> <p>Follow‐up: 6 months after start of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> <b>300 per 1000</b> (125 to 721) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> </p> <p>(0.25 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 12</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1</sup> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MRONJ:</b> medication‐related osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b>  we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b>  we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty: </b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to imprecision and very serious risk of bias (unclear selection bias and detection bias, high risk of performance bias, attrition bias and reporting bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Teriparatide 56.5 μg weekly (experimental) versus teriparatide 20 μg daily (control) in addition to standard care for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012432-tbl-0012"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Clinical staging of MRONJ</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRONJ stage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT RISK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No apparent necrotic bone in patients who have been treated with oral or intravenous bisphosphonates </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>STAGE 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No clinical evidence of necrotic bone but nonspecific clinical findings, radiographic changes, and symptoms </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>STAGE 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exposed and necrotic bone or fistulas that probes to bone in patients who are asymptomatic and have no evidence of infection </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>STAGE 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exposed and necrotic bone or fistulas that probes to bone associated with infection as evidenced by pain and erythema in the region of exposed bone with or without purulent drainage </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>STAGE 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exposed and necrotic bone or a fistula that probes to bone in patients with pain, infection, and ≥ 1 of the following: exposed and necrotic bone extending beyond the region of alveolar bone (i.e. inferior border and ramus in mandible, maxillary sinus, and zygoma in maxilla) resulting in pathologic fracture, extraoral fistula, oral antral, or oral nasal communication, or osteolysis extending to inferior border of the mandible or sinus floor </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>From the American Association of Oral and Maxillofacial Surgeons position paper on medication‐related osteonecrosis of the jaw‐‐2014 update (<a href="./references#CD012432-bbs2-0107" title="RuggieroSL , DodsonTB , FantasiaJ , GooddayR , AghalooT , MehrotraB , et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery2014;72(10):1938-56. [PMID: 25683041]">Ruggiero 2014</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Clinical staging of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012432-tbl-0013"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Previous searches</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The initial electronic search of 2016 retrieved 1105 references after de‐duplication. After screening the titles and abstracts, we excluded all but 23 references from further evaluation. We examined the full text of the remaining 23 articles and found that eight references relating to five studies met the prespecified inclusion criteria and were therefore included in this review. We identified four additional studies that are ongoing and listed these under <a href="./references#CD012432-sec-0152" title="">Characteristics of ongoing studies</a>. We excluded 11 full‐text articles for reasons noted in the <a href="./references#CD012432-sec-0151" title="">Characteristics of excluded studies</a> table. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Previous searches</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/full#CD012432-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dental examinations at three‐month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 MRONJ (incidence proportion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.02, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 MRONJ (incidence rate: MRONJ cases per patient‐year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dental examinations at three‐month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Plasma rich in growth factors inserted into the postextraction alveolus in addition to standardised medical and surgical care (experimental) versus standardised medical and surgical care alone (control) for prophylaxis of MRONJ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 MRONJ (incidence proportion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Plasma rich in growth factors inserted into the postextraction alveolus in addition to standardised medical and surgical care (experimental) versus standardised medical and surgical care alone (control) for prophylaxis of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 MRONJ after tooth extraction (assessed with: absence of complete mucosal integrity) at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Hyperbaric oxygen as an adjunct to conventional therapy (experimental) versus conventional therapy (control) for treatment of MRONJ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Healing of MRONJ at last contact <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.77, 3.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Hyperbaric oxygen as an adjunct to conventional therapy (experimental) versus conventional therapy (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Autofluorescence‐guided bone surgery (experimental) versus tetracycline fluorescence‐guided bone surgery (control) for treatment of MRONJ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Healing of MRONJ (defined as mucosal integrity) at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.86, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Autofluorescence‐guided bone surgery (experimental) versus tetracycline fluorescence‐guided bone surgery (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) compared to platelet‐rich fibrin alone (control) for treatment of MRONJ.</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Healing of MRONJ (defined as full mucosal coverage without clinical or radiographical evidence of MRONJ) after 16 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.94, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Bone morphogenetic protein‐2 together with platelet‐rich fibrin (experimental) compared to platelet‐rich fibrin alone (control) for treatment of MRONJ.</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Autofluorescence‐guided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Healing of MRONJ (defined as full mucosal coverage and no signs of residual infection) at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.85, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Autofluorescence‐guided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Healing of MRONJ (defined as absence of infection and mucosal integrity without fistula) at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.90, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Healing of MRONJ (defined as absence of infection, mucosal integrity without fistula,  and no need for re‐intervention) at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.04, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Platelet‐rich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Concentrated growth factor and primary wound closure (experimental) versus primary wound closure only (control) for treatment of MRONJ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Healing of MRONJ (assessed with: mucosal integrity) at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.81, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Concentrated growth factor and primary wound closure (experimental) versus primary wound closure only (control) for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Teriparatide 20 μg daily (experimental) versus placebo (control), in addition to standard care, for treatment of MRONJ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Healing of MRONJ (defined as absence of any unresolved lesion) at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.31, 2.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Teriparatide 20 μg daily (experimental) versus placebo (control), in addition to standard care, for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012432-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Teriparatide 56.5 μg weekly (experimental) versus teriparatide 20 μg daily (control), in addition to standard care, for treatment of MRONJ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Healing of MRONJ (defined as partial or complete remission) at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.25, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Teriparatide 56.5 μg weekly (experimental) versus teriparatide 20 μg daily (control), in addition to standard care, for treatment of MRONJ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012432.pub3/references#CD012432-tbl-0024">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012432.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012432-note-0023">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012432-note-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012432-note-0022">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012432-note-0020">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD012432-note-0019">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012432-note-0018">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012432-note-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012432-note-0017">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012432\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012432\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012432\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012432\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012432\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012432.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012432.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012432.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012432.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012432.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718846382"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012432.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718846386"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012432.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dda4ede57935f',t:'MTc0MDcxODg0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 